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One of the great successes of modern medicine is that it has transformed relatively 
acute causes of death (i.e. cardiovascular disease, organ failure and some cancers) 
into chronic diseases. In the developed world, most people will now grow old and, 
over decades, accumulate various chronic diseases before eventually succumbing 
to a final illness. Older people in their final years are commonly prescribed 
multiple medications to manage their chronic diseases. These medications may 
ameliorate symptoms, prevent future adverse health events and extend life. 
However, the use of multiple medications is also associated with higher risks of 
side-effects, adverse drug-interactions, and adherence problems. Furthermore, as 
older people become increasingly frail, the use of multiple medications may be 
considered burdensome for them or even futile. For frail older patients taking 
multiple medications, when does the scale shift from net benefit to net harm? If 
declining health and death are unavoidable, it follows logically that there must 
come a point when patients no longer benefit from certain chronic disease 
therapies. 
This thesis primarily attempts to address two important questions. Firstly, 
how can we recognize when older people are approaching end-of-life? For such 
people, a personalized approach that prioritizes comfort and symptom relief is 
likely to be more appropriate than the pursuit of strict chronic disease targets. 
Secondly, when attempting to address a frailer older person’s complex and 
burdensome medication regimen, how do we separate essential medications from 
those that are dispensable?  
The thesis consists of seven chapters. The first chapter is an introduction, 
divided into three sections: (i) what is deprescribing and why is it important? (ii) 
recognizing when older people are approaching end-of-life; (iii) operationalizing 
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deprescribing for older people approaching end-of-life. Chapter 2 describes the 
application of a mortality prediction model, previously validated in North America, 
to a cohort of hospitalized older adults in Ireland. Chapter 3 examines the 
prevalence of potentially inappropriate prescribing in hospitalized older patients 
who are in the last year of life. Chapter 4 compares the performance of two 
structured deprescribing-decision tools using 100 standardized clinical cases.  
Chapter 5 examines the effect of applying a novel and recently validated 
deprescribing tool – STOPPFrail Criteria –to the medication regimens of frail, 
older, hospitalized patients who are undergoing transition to long-term nursing 
home care. A randomized controlled design is used to determine the impact of 
STOPPFrail on the number of prescribed medications, a variety of healthcare 
outcomes, quality of life and mortality. In chapter 6, applying information gathered 
from the previous chapters, a new version of STOPPFrail is developed and 
validated using modified Delphi methodology. Finally, in chapter 7, I discuss 
questions arising from these studies and suggest topics for future research.  
The thesis is presented in the form of a Publication-based Thesis. The 
‘Methods’ and ‘Results’ sections of chapters 2, 3, 4 and 5 are largely unchanged 
from how they are presented in respective peer-reviewed published papers; the 
‘Introduction’ and ‘Discussion’ sections have been modified in certain instances to 
improve the coherence of the thesis. PDF versions of published articles and 











“Medicine is not only a science; it is also an art. It does not consist of 
compounding pills and plasters; it deals with the very processes of life, which must 
















































1.1 WHAT IS DEPRESCRIBING AND WHY IS IT IMPORTANT? 
 
1.1.1 Definition: 
The term ‘deprescribing’ first appeared in the English literature in 2003.1 
Woodward, in an early review article, outlined the principals of deprescribing. 
These included: 
i. reviewing all current medications, 
ii. identifying medications to be discontinued, substituted or reduced 
iii. planning a deprescribing regimen in partnership with the patient and 
iv. frequently reviewing and supporting the patient. 1  
 
Since then, several new definitions have been proposed. 2-4 A 2015 systematic 
review of the literature by Reeve et al. was conducted to determine whether a 
standardized definition of deprescribing could be reached to inform future research 
on the subject.5 The most common characteristics of the various definitions were 
used by the authors to develop a new definition:  
“Deprescribing is the process of withdrawal of an inappropriate medication, 
supervised by a health care professional with the goal of managing polypharmacy 
and improving outcomes.” 
 
1.1.2 When is medication considered ‘inappropriate’? 
It may be informative to firstly consider the concept of “appropriate” prescribing. 
Parish, in his influential paper, discussed this concept in the context of limited 
healthcare resources, and stated that prescribing is appropriate when it is safe, 
effective and economic.6 Cribb and Barber later expanded on this framework and 
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suggested that the appropriateness of prescribing could be evaluated by considering 
three overlapping domains:7 
1. The drug has the right technical properties –broadly, this refers to the 
efficacy and safety of the medication. Can the drug fulfil its goal of 
benefitting the patient? Also, do the potential benefits of the drug outweigh 
the potential risks? Important considerations here include other prescribed 
drugs, co-morbidities and the prognosis of the patient.  
2. The drug aims to fulfil the goals of the patient – Often the respective goals 
of the physician and patient easily align, for example, in the prescribing of 
analgesics for pain. Disease control (e.g. antihypertensive therapies) or 
preventive medications (e.g. anticoagulants) do not usually make the patient 
feel better and therefore it is important that the prescriber translates 
‘technical’ goals into goals that are meaningful to the patient.7 Shared-
decision making is now widely advocated as the ideal model for treatment 
decision-making and failure to elicit and address patients' individual 
concerns contributes to treatment nonadherence.8-10 Generally a patient 
wants to get better or remain well and this fact is the background against 
which prescribing decisions are made. When a patient is approaching end-
of-life, achieving technical goals may be of limited or no benefit to the 
patient, and it is more appropriate to place greater emphasis on important 
patient-related goals (i.e. control of symptoms).  
3. The drug serves the general good –the wider implications of prescribing 
decisions also need to be considered. There are social, biological and 
economic consequences of poor prescribing practices. A low threshold for 
prescribing medicines to treat depressive or anxiety symptoms may 
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medicalize aspects of normal life experience.11 Indiscriminate prescribing 
of broad-spectrum antibiotics is a major contributor to the growing problem 
of bacterial resistance. Finally, healthcare resources are limited and there is 
an opportunity cost to interventions. The opportunity cost of prescribing an 
ineffective or unsafe medication can be measured by the health benefits 
(life years saved, quality adjusted life years [QALYs] gained) that could 
have been achieved had the money been spent on an alternative intervention 
or healthcare programme.12 
 
Using this model, a medication could be considered inappropriate if it is not 
effective or safe, if it does not aim to fulfil the treatment goals of the patient, or if it 
does not serve ‘the general good’.  Ethical and practical judgement is of course 
necessary to weigh up competing considerations between these domains. For 
example, any expectation of efficacy or value for money depends on the patient 
adhering to the medication, and this is in itself, at least partly, contingent on the 
drug having meaningful value to the patient. Likewise, if a patient approaching 
end-of-life wishes to continue a medication (e.g. a benzodiazepine) despite 
concerns about safety, it may be considered inappropriate and potentially unethical 
to deprescribe the medication against the patient’s wishes.13 
 
1.1.3 Polypharmacy  
Polypharmacy refers to the concurrent use of multiple medications by an 
individual. Various definitions are present in the literature but, most commonly, 
polypharmacy refers to the use of five or more daily medications.14 In the United 
States, 39% of adults aged 65 years or older take 5 or more daily medications.15 In 
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Europe, almost 25% of nursing home residents take 10 or more daily 
medications.16 
Polypharmacy is strongly associated with multimorbidity (i.e.  two or more 
chronic medical conditions in an individual17). The prevalence of multimorbidity 
increases steadily with age, and in developed countries, more than half of all adults 
aged 65 years or older have three or more chronic conditions. 18, 19 The 
management of multimorbidity in older people is challenging. Chronic disease 
treatment guidelines, which inform physician practice, are generally derived from 
single disease randomized trials. These trials also commonly exclude frailer 
multimorbid older individuals.20 Thus, when multiple treatment guidelines are 
applied to multimorbid older adults, they commonly result in lengthy, problematic 
prescriptions.20-24 Figure 1.1 illustrates some of the difficulties associated with 
uncritically applying several single-disease treatment guidelines to an older patient 
with multimorbidity.  
Polypharmacy is also likely to be driven by nonclinical factors. Available 
evidence suggests that prescribing decisions are strongly influenced by the 
expectations that patients bring to the consultation with their doctors.25-29 For some 
patients, more investigations and more treatment may be perceived as better care.30 
Perhaps an even more important determinant, however, is the perception that 
doctors have of their patients’ expectations. In two large primary care studies 
conducted in England and Australia, doctors’ perceptions of their patients’ 
expectations, rather than patients’ actual expectations, were the strongest predictor 
of the decision to prescribe.31,32 Clinicians are often poor at detecting expectations 
specific to the patient visit,33 generally opt for doing rather than not doing in 
response to health threats (the so-called “treatment imperative”),34,35 and  
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Figure 1.1:  Problems associated with application of chronic disease guidelines a 




may sometimes favour the perceived efficiency of prescribing a medication over 
spending additional time and effort explaining why it may not be necessary.29, 36 
 
The enthusiasm for treatment on the part of doctors and patients reflects a 
tendency to overestimate the benefits and underestimate the harms of medical 
interventions.30, 37, 38 Thomas, in 1978, referred to this tendency as the “therapeutic 
illusion”.39 He contended that “the patient who is made better with no treatment 
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will also be made better with treatment”.39 When a patient is prescribed 
unnecessary treatment and later gets better, the improvement serves to confirm to 
the doctor and the patient that the correct course of action was taken (i.e. 
confirmation bias). This creates a relationship between treatment and recovery that 
is non-existent. When physicians, in particular, believe that the medications they 
prescribe are more effective than they actually are, the result can be unnecessary 
and costly care. 
Inappropriate prescribing and polypharmacy in the context of ageing and 
declining health pose three important problems. Firstly, patients are placed at an 
increased risk of adverse drug reactions. Secondly, if treatments are unnecessary, 
patients are subjected to complicated, burdensome treatment regimens. Thirdly, 
inappropriate prescribing and polypharmacy are associated with increased 
healthcare costs.  
 
1.1.4 Adverse drug reactions  
Adverse drug reactions (ADRs) are defined as ‘an appreciably harmful or 
unpleasant reaction resulting from an intervention related to the intentional use of a 
medicinal product, which predicts hazard from future administration and warrants 
prevention or specific treatment, or alteration of the dosage regimen or withdrawal 
of the product’.40 ADRs may be easy to recognize when the syndrome fits the 
known adverse effect pattern of the drug (e.g. acute kidney injury or 
gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs) 
and there is a time relation between use of the drug and the occurrence of the 
reaction. ADRs, however, can be difficult to recognize, particularly in older people 
with complex medical issues, and may manifest as nonspecific symptoms such as 
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fatigue, poor appetite, memory loss, impaired balance and constipation.41  
Unfortunately, these symptoms may be misinterpreted as  representing new clinical 
problems (prompting the prescription of new medications), or perhaps worse, may 
be attributed to normal ageing.13, 42  
Older age, in addition to being accompanied by increased chronic disease 
burden and complexity, is also associated with a range of physiological changes 
that alter drug pharmacokinetics (i.e. absorption, distribution, metabolism, and 
excretion) and pharmacodynamics (the effect of the drug on the organism). These 
physiological changes, which may be enhanced by frailty and declining health, 
place older people at increased risk of ADRs.  Some of the important physiological 
changes and their clinical implications are summarized in Tables 1.1 and 1.2.  
Due to difficulties with detection, varying ADR definitions, as well as 
inconsistencies in the application of rigorous standardized causality assessment 
methods in prospective studies, accurate and reliable data about the true incidence 
and consequences of ADRs in older people are limited.41 Best available evidence 
indicates that approximately 5% -10% of hospital admissions involving older 
adults are attributable to ADRs.43, 44 Amongst hospitalized older adults, the 
incidence of clinically significant ADRs ranges from 6.5% -21%.45-48 Evidence 
from prospective studies indicate that ADRs prolong hospital admissions46 and are 
an important cause of mortality in hospitalized older patients.45, 49  
There are no well-designed prospective studies examining ADR incidence 
in older people approaching end-of-life.  However, valuable ADR data are 
available for nursing home residents who are generally representative of the frailest 
population of older adults. The most important study is a prospective cohort study 
involving 2916 nursing home residents in 18 nursing homes in Massachusetts who 
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were observed for a mean of 9.9 months. 50, 51 Adverse drug events (ADEs), defined 
as injuries resulting from the use of a drug, were categorized as preventable (i.e. 
related to errors in prescribing, dispensing, administration or monitoring) or non-
preventable (i.e. not related to errors in these steps). Potential events were reviewed 
by two trained physicians and were included in the analysis only if an ADE was 
considered ‘highly probable’. Overall, there were 546 ADEs during the observation 
period which equated to a rate of 1.89 ADEs per 100 resident-months. The authors 
of the study reported that, for an average-sized nursing home in the United States 
(106 residents), this would amount to approximately 24 ADEs per year.50 
Importantly, the number of daily medications was also associated with an increased 
risk of an ADE; the odds ratio (OR) associated with taking 5 to 6 medications 
(versus <5 medications per day) was 2.0 (confidence interval [CI] 1.2 -3.2); 7 to 8 
medications, 2.8 (CI, 1.7 -4.7); and 9 or more medications, 3.3 (CI, 1.9 -5.6).51 The 
association of polypharmacy with increased ADR/ADE risk in nursing home 
residents has also been demonstrated by other investigators.52, 53 
Overall, the literature indicates that polypharmacy is an important risk 
factor for drug-related harm in older adults. ADRs seem to be particularly 
important in the acute setting when transitions of care (potentially resulting in 
prescribing errors), introduction of new medications (increased risk of prescribing 
errors, drug-drug and drug-disease interactions) and acute illness (increased risk of 







Table 1.1: Pharmacokinetic changes associated with ageing and declining 
health    
 Changes in 
older adults 
Additional 
changes that may 





Absorption Reduced gastric 
acid secretion.54 
 Reduced absorption of calcium, iron 
and vitamin B12. This effect may be 
further enhanced by the use of anti-
ulcer medications. 
Distribution Relative 
reduction in total 
body water and 
muscle mass and 
a relative 




albumin may be 
seen in older 












the blood brain 
barrier (BBB).55 
Body composition 
changes are likely 
to be exaggerated 










loss of equal 
amounts of fat and 
muscle mass with 
preservation in 
total body water.56 
 
Albumin may be 
very low in patients 
with terminal 




Hydrophilic drugs (e.g. gentamicin, 
digoxin, ethanol) have smaller 
volumes of distribution in older adults 
and therefore higher serum 
concentrations.  Increased serum 
concentrations lead to an increase in 
elimination which limits the 
importance of this effect. Lipophilic 
drugs (e.g. diazepam, lignocaine) have 
larger volumes of distribution (lower 
serum concentrations) but may be 
more difficult to clear.  
 
The main factor determining drug 
effect is its free concentration. 
Increased levels of unbound drug (i.e. 
due to low albumin) lead to a 
proportionate increase in elimination, 
again, limiting the importance of this 
effect. 
Overall, alterations to body 
composition and serum drug-binding 
proteins, alone, are unlikely to have 
significant clinical implications in 
healthy older adults.54, 57  
 
Increased permeability of the BBB 
may increase risk of neurological 
ADRs. 
Metabolism Reduction in 
liver size and 
blood flow.58 

















reduce phase I 
metabolism.59, 60 
 
Frailty may lead to 
reduction in phase 
II metabolism.61, 62 
Several ACE inhibitors (e.g. enalapril, 
perindopril) are prodrugs and need to 
be activated in the liver. This 
activation may be impaired in older 
patients, especially those with severe 
heart failure and liver congestion, 
leading to delays in onset of action. 54, 
63, 64 
 
Bioavailability and half-life of certain 
opioids (e.g. tramadol) may be 
increased in patients with primary and 















GFR may be 





The majority of drugs and/or their 
metabolites are excreted by the 
kidneys.  
 
Reductions in GFR may lead to drug 
accumulation and toxicity. 
Accumulation of drugs with a narrow 
therapeutic index, such as gentamicin, 
lithium and digoxin, may cause serious 
adverse effects.54 
 
Frailty and cachexia are associated 
with reduced muscle mass and, 
therefore, serum creatinine and GFR 
calculators may underestimate renal 
impairment.67 
Legend: ACE = angiotensin converting enzyme; ADRs = adverse drug reactions; BBB = 
blood brain barrier; GFR = glomerular filtration rate  
 
 
Table 1.2:  Pharmacodynamic changes associated with ageing  
Drugs with age-related increase in 
pharmacodynamic effect 













sedation, risk of 
falls, cognitive 
decline69 
Furosemide Reduced peak 
diuretic response 
(i.e. higher doses 
required to 


















1.1.5 Burden and futility of medications at the end of life 
Morin et al. examined patterns of prescribing in the last year of life in a nationwide 
longitudinal cohort study of 511,843 older adults in Sweden who died between 
2007 and 2013.74 Between the 12th month and the final month before death, the 
proportion of older adults with major polypharmacy (prescribed ≥10 regular 
medications) rose from 30.2% to 47.2% and the mean (standard deviation [SD]) 
number of prescription drugs increased from 7.6 (4.4) to 9.6 (4.7). Even when 
analgesic drugs were removed, the trend of increasing numbers of prescription 
medications in the last year of life persisted. In the month before death, 53.8% of 
patients were prescribed anti-thrombotics, 34.6% were taking supplements for 
anaemia, 20% were prescribed calcium or potassium supplements, 35.1% were 
prescribed gastric acid suppressants and 16.3% were prescribed lipid –lowering 
agents.74 It is important to note that a significant proportion of these deaths may 
have been unexpected, and high-level polypharmacy, in many cases, may have 
been considered reasonable by attending physicians. However, several other 
investigators, focussing on patients with advanced cancer and other life-limiting 
illnesses, have also shown that low value medications are commonly prescribed at 
end of life.75-77  
In a recent cross-sectional study of 5406 nursing home residents with 
advanced dementia, Tija et al. reported that just over half of all residents were 
prescribed at least one medication of questionable benefit.78 Cholinesterase 
inhibitors (36.4%), memantine (25.2%) and lipid-lowering agents (22.4%) were the 
most commonly prescribed of such questionable medications. Most of these 
patients received between 5 and 15 medications daily.79 These findings are 
important because nursing home residents with advanced dementia frequently have 
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problems with dysphagia and aspiration and, therefore, drug administration, in 
addition to being potentially futile, may also be burdensome or even harmful. 80, 81 
The concept of therapeutic futility is an important one in medicine. 
Hippocrates wrote that physicians should “refuse to treat those who are 
overmastered by their diseases, realizing that in such cases medicine is 
powerless”.82 The Oxford English Dictionary defines futile as “incapable of 
producing any useful result; pointless”.83 The word futile relates to a specific action 
whereas futility refers to the relationship between an action and a specific goal. In 
the medical context, therefore, futility could be defined as a “clinical action serving 
no useful purpose in attaining a specified goal for a given patient.”84  
“No useful purpose”, however, implies that there is no possibility of 
achieving a specified goal. There are always exceptions and some authors have 
suggested defining futility as a less than 1%, 2% or 5% chance of success.85, 86 
These thresholds can also be expressed as the number needed to treat (i.e. the 
number of patients that need to be treated for one patient to benefit [NNT]). 
Defining futility as a 1%, 2% or 5% chance of success translates into an NNT of 
100, 50 or 20, respectively. While attractive in terms of concreteness, these 
thresholds need to be interpreted with caution. NNT figures are derived from 
randomized controlled trials that usually exclude older patients with significant 
frailty or advanced disease and reflect the chance of success for the “average” 
patient with an average set of risk factors.21 Thus, applying RCT evidence to an 
individual older patient with marked frailty or advanced disease could substantially 
over- or underestimate chance of success for that individual. Even so, it is 
instructive to note most patients do not benefit from preventive medications that 
are commonly prescribed for them (Table 1.3). 
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Table 1.3:  Number needed to treat data for commonly prescribed preventive 
therapy 
Drug Specified outcome  NNT for benefit 
Statins Primary prevention87 
  
 
Secondary prevention (heart disease, 
treatment for 5 years)88, 89 
 
217 (nonfatal MI) 
313 (nonfatal stroke) 
 
83 (death) 
39 (nonfatal MI) 
125 (nonfatal stroke) 
Bisphosphonates Fracture prevention in 
postmenopausal women with no 
previous fracture (treatment for 3 
years)90, 91 
 
Fracture prevention in 
postmenopausal women with prior 
fracture or very low bone density 






20 (vertebral fracture; 
many of these 
subclinical) 
100 (hip fracture) 
Calcium and 
vitamin D 
Fracture prevention in community 
dwelling older adults92, 93  
 
 
Fracture prevention in high risk 






111 (hip fracture); no 
benefit with vitamin D 
alone 
Aspirin Primary prevention (treatment for 
6.6 years)95 
 
Secondary prevention (treatment for 





77 (non-fatal MI) 
200 (non-fatal stroke) 
Legend: MI = myocardial infarction; NNT = number needed to treat 
 
As shown in Table 1.3, RCT evidence indicates that 100 postmenopausal women 
with a prior history of fracture would need to be treated for 3 years with a 
bisphosphonate to prevent one hip fracture. 90, 91 Treating 1000 patients for 3 years 
will prevent 10 hip fractures which, even at this level, is likely to represent an 
important public health intervention. However, when an older person is 
approaching end-of-life, and care needs to be individualized, bisphosphonate 
therapy may be considered a low-priority intervention.  
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1.1.6 Costs associated with inappropriate prescribing 
Morgan et al. measured the frequency of prescribing and cost of potentially 
inappropriate medications (PIMs) dispensed to drug plan enrolees aged ≥65 years 
in 6 provinces in Canada in 2013.98 PIMs were defined using the American 
Geriatrics Society’s 2012 version of the Beers Criteria, an explicit list of 
medications to be avoided or used with caution in older adults. Overall, 37% of 
older people took one or more prescription Beers Criteria PIMs. Extrapolating from 
these data, it was estimated that $419 million in total, or $75 per older Canadian, 
was spent on PIMs in the community setting in 2013.98 In a similar study 
conducted in Ireland by Cahir et al., PIM prescribing (defined by Screening Tool of 
Older Peoples Prescriptions [STOPP]) was estimated to account for approximately 
9% of the overall expenditure on pharmaceuticals in those aged ≥70 years. 99 Only 
the direct cost associated with PIM prescribing, and not the consequences, was 
measured in these studies.  
Recently Formica et al. conducted a systematic review of observational 
studies that evaluated the economic impact of preventable ADRs.100 Only 
observational studies in the United States and Europe were included. While limited 
by heterogeneity in methods, outcome definitions and reporting, the review showed 
that costs due to preventable ADRs in a hospital inpatient setting ranged from 
€2,851 to a maximum of €9,015 while those in an outpatient setting ranged from 






1.2 RECOGNIZING WHEN OLDER PEOPLE ARE APPROACHING 
END OF LIFE 
 
1.2.1 Trajectories of disability in the last year of life 
Glaser and Strauss in 1968 described three patterns of dying: 101 sudden, 
unexpected deaths; expected deaths, both with a short and prolonged dying phase; 
and entry-re-entry deaths, where individuals had recurrent hospital admissions in 
the last months of life. More recently, these concepts have been expanded and 
expressed as trajectories of disability in the last year of life. The most important 
study examining these trajectories has been the Precipitating Events Project.102-104 
This longitudinal study originally enrolled 754 community dwelling older persons 
aged 70 years or older in the United States (US) between March 1998 and October 
1999. In order to be eligible, participants had to be independent in 4 essential 
activities of daily living (ADLs): washing, dressing, walking and transferring from 
a chair to a standing position. Comprehensive home-based assessments were 
completed at baseline and patients were followed prospectively with further 
comprehensive assessments at 18-month intervals. Participants, or a designated 
surrogate, had monthly telephone interviews primarily focussed on determining 
participants’ abilities across the 4 ADLs. Clinically distinct trajectories of disability 
in the last year of life were identified using a statistical method called trajectory 
modelling, which is a form of latent class modelling. The most recent update from 
this longitudinal study was in 2015 by which time 552 participants had died.104 In 
the last year of life, six distinct trajectories of disability were identified (Figure 
1.2): no disability, catastrophic disability, accelerated disability, progressively mild 










Importantly, the results indicate that approximately 50% of older people need 
assistance with basic ADL functioning 12 months prior to death. This finding has 
also been reported in larger, albeit less rigorous, cohort studies.105, 106 Of those who 
were disability-free 12 months prior to death, one third remained disability-free, 
while the remainder varied in terms of the timing and rate of development of 
disability. Apart from advanced dementia, which was characterized by high levels 
of disability throughout the last year of life, other common causes of death (i.e. 




Values for ‘Severity of disability’ represent the mean number of disabled activities of daily living 
(from 0 to 4). Black lines depict predicted trajectories, and companion lines depict observed 
trajectories. Ῑ bars represent 95% confidence intervals for predicted disability scores. 
Reproduced with permission.104 
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1.2.1 Hospitalizations as a marker of declining health 
The majority of people in the last year of life are admitted to hospital on at least 
one occasion and, for many of these people, hospitalizations are frequent and 
prolonged.107, 108 Goldbury et al. measured healthcare utilization amongst all adults 
who died in a 12 month period in New South Wales, Australia.107 Of the 45,749 
decedents, 82% were admitted to hospital in the last year of life, 24% had more 
than 3 hospital admissions and 35% spent more than 30 days in hospital. Lyons and 
Verne reported similar findings in England where 78% of people had at least one 
hospital admission in the year before death and the mean length of stay in hospital 
was 29.7 days.108  
Because older people are frequently admitted to hospital in the year prior to 
death, it follows then that there is an opportunity to identify people who have a 
high one-year mortality risk. The value of identifying high risk patients is that 
important discussions about values, priorities and goals of care can take place. 
Amongst adults of all ages hospitalized with acute illness, 20%-28% will be 
deceased within 1 year.109, 110 Important factors associated with an increased 1-year 
mortality risk in hospitalized patients include increased age,109-111 impaired 
functional status,111, 112 delirium,113 and low socioeconomic status.109  
Impaired functional status, as well as ADL decline during hospitalization, 
appears to be particularly important. Boyd et al. examined outcomes in the year 
following discharge for older people with hospitalization associated disability.112 
Compared with older people who were discharged from hospital with no change in 
ADL functioning, those discharged with new or additional disability were 
significantly more likely to be deceased at one year (41.3% versus 17.8%).112 In the 
Precipitating Events Project, Gill et al. evaluated the role of intervening hospital 
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admissions on the course of disability in the last year of life.104 All six disability 
trajectories were closely matched by the monthly prevalence of hospital admissions 
and these findings were confirmed using a set of multivariable models that adjusted 
for several potential confounders.104 The results indicate that acute illness leading 
to hospitalization plays a significant role in the disabling process at the end of life. 
The results of these studies also suggest that new or additional disability associated 
with hospitalization in an older person is often a sentinel event and should, perhaps, 
prompt a discussion about goals of care. 
 
1.2.3 Prognostic estimation 
Prognostication relies upon an ability to accurately estimate survival. Prognostic 
estimates may be formulated subjectively (i.e. clinician prediction) or objectively 
(i.e. using prognostic models). Clinician prediction has the advantage of being 
instantaneous and convenient, and while it may incorporate known prognostic 
factors in its determination, accuracy will undoubtedly vary depending on the 
knowledge, experience and personality of the clinician. Indeed, most studies have 
found that clinicians generally give optimistic estimations of life expectancy.114-116 
Christakis and Lamont described clinicians’ prognostic accuracy in terminally ill 
patients. 115 In this study, 343 doctors provided survival estimates for 468 
terminally ill patients at the time of hospice referral. Just 20% of predictions were 
accurate (i.e. predicted survival rate within ±33% of actual survival) and overall, 
doctors overestimated survival by an average factor of 5.3. The most experienced 
clinicians tended to be most accurate, while, counterintuitively, the longer the 
duration of the doctor-patient relationship, the greater the likelihood of an 
inaccurate prediction.115  
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The accuracy of clinician prediction may depend on how the question the 
question is asked.117- 118 As outlined, the temporal question – “how long will this 
patient live?” –is likely to be associated with overly-optimistic predictions. The 
surprise question asks the clinician “would you be surprised if this patient were to 
die within the next (insert specific time frame; usually 12 months)?” 119 Of course, 
the threshold for “surprise” will inevitably vary between healthcare professionals. 
But, rather than being asked to provide an estimate of life expectancy, as in the 
temporal question, the answer is binary (yes or no), and essentially functions as a 
method of separating those with an intermediate-to-high probability of dying (the 
clinician answers that he/she would not be surprised if the patient died within the 
specified time period i.e. surprise question positive [SQ+]) from those with a low 
probability of dying (the clinician would be surprised i.e. surprise question negative 
[SQ-]). The surprise question is widely used as a method for identifying patients 
who might benefit from hospice and palliative care.120, 121 Its accuracy was recently 
assessed in two systematic reviews: Downar et al.122included studies where the 
primary outcome (death) was measured at least 6 months after the surprise question 
was asked; in contrast, White et al.123 included all studies that examined the use of 
the surprise question, even those that used time scales as short as 7 days. Downar et 
al.’s review demonstrated that the surprise question has better discrimination for 
patients with cancer that those patients with non-cancer illnesses (concordance [c] 
statistic 0.83 versus 0.77). The pooled accuracy for White et al.’s review was 0.75. 
While, the reviews showed that the surprise question will lead to the detection of 
many ‘false positives’, this simple method appears to be very effective at excluding 
patients with longer survival times (negative predictive value >90% in both 
reviews). Overall, it seems that the surprise question has value as part of a wider 
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prognostic assessment and, in particular, may be helpful in excluding patients who 
are not necessarily approaching end of life.  
Multiple prognostic models have been developed in recent years to predict 
mortality risk in older people. The quality and limitations of non-disease-specific 
prognostic models for older people were evaluated in 2012 systematic review by 
Yourman et al.124 The authors concluded that there was insufficient evidence to 
recommend any of the 16 models that met the study requirements for clinical use. 
Very few of the indices had been tested in terms of transportability (i.e. tested in 
different patients, in different geographical regions, at different times). Of 
particular concern was the fact that just two of the indices had been validated by 
investigators who were not involved in the development of the same indices.  
Since that review, two important prognostic models have been developed 
and validated. The first is the Hospital patient One-year Mortality Risk (HOMR) 
model which uses administrative data to predict one-year mortality risk in 
hospitalized adults aged 18 years and older. 125, 126 It was developed and validated 
in over 3 million hospitalized adult (i.e. 18 years) non-psychiatric patients in 
Canada and the United States. The HOMR model was highly discriminative, with a 
c statistic ranging from 0.89 to 0.92. The HOMR model has not been validated in 
an exclusively older hospitalized population nor has it been externally validated by 
independent investigators not involved in its development. The second recently 
developed prognostic model, the Q-Mortality risk algorithm, uses routinely 
collected primary care data to predict 1-year mortality risk in older community 
dwelling adults. 127 It was developed and validated using data from almost 2 million 
patients in the United Kingdom and was shown to be highly discriminative (c 
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statistic 0.85). Similar to the HOMR model, the Q-mortality risk algorithm has yet 
to be independently validated.  
 
1.2.4 Frailty status and risk of death 
Frailty is broadly characterized as a late-life vulnerability to adverse health 
outcomes 128-131 A single operational definition of frailty has yet to gain widespread 
acceptance among experts primarily because there has been a proliferation of 
frailty measurement tools with differing conceptual bases in the medical literature 
in the last 2 decades. The two conceptual models that have been most cited in the 
literature, and therefore merit particular attention, are the frailty phenotype (FP) 
and the frailty index (FI). 
The FP, developed by Fried et al., recognizes frailty as a distinct clinical 
syndrome that commonly, though not always, overlaps with disability and co-
morbidity.131 The core characteristics of the phenotype were first identified and 
validated in 2001 through a consensus survey of 62 geriatricians and then 
operationalized in the Cardiovascular Health Study, a large-cohort study of over 
5,300 community-dwelling older men and women in the United States.132 An 
individual is considered frail if he or she meets three of the following five criteria: 
(i) weakness as measured by low grip strength, (ii) slow walking speed, (iii) low 
level of physical activity, (iv) low energy or self-reported exhaustion, and (v) 
unintentional weight loss. Individuals who meet one or two criteria are classified as 
pre-frail while those who meet none of the criteria are considered non-frail. The 
relevant thresholds for each of these measurements are shown in Table 1.4.  
The FI, developed by Rockwood et al., conceptualizes frailty as an 
accumulation of health deficits over the course of one’s life.133, 134 Health deficits 
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are defined by clinical symptoms, signs, diseases, disability, laboratory, 
radiological or electrocardiographic abnormalities or social characteristics. Frailty 
is then measured by dividing the number of health deficits present by the number 
of health deficits measured. Therefore, a person with 8 deficits out of 40 measured 
has a frailty index of 0.20. In general, health deficits should be acquired, age-
related and associated with adverse outcomes.133 The number (usually 30 to 70 
items) and type of deficits measured can vary depending on the population studied 
but the construction of the index should follow established guidelines.135  
 




Weakness Grip strength: lowest 20% (by sex, body mass 
index) 
Slowness Walking time/ 15 feet: slowest 20% (by sex, height) 
Low level of physical 
activity 
Kcal/ week: lowest 20% 




Weight loss > 10Ib (4.5kg) lost unintentionally in prior year 
 
A recent systematic review and meta-analysis of 19 studies indicated that the FI 
was a significant predictor of mortality, with higher FI scores associated with a 
significantly higher mortality risk.136 Indeed, in head-to-head comparisons, the FI 
has been shown to be superior to the FP in predicting mortality in older people.137, 
138 However, the FI has certain inherent limitations. In addition to limited face 
validity for practicing clinicians, counting deficits is likely to be onerous and 
impractical in routine clinical practice. Recognizing this, Rockwood et al. 
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developed the Clinical Frailty Scale (CFS; see Figure 1.3).139 Here, the care 
provider assigns a frailty score ranging from 1 (very fit) to 9 (terminally ill) using a 
decision support chart with succinct, clear descriptors for each of the nine levels of 
frailty. Clinical judgement is required of the care provider to assign the appropriate 
score. The CFS has been shown to correlate very closely with the FI in terms of 
predicting adverse outcomes in older people including institutionalization and 
death.139 In recent studies by Ritt et al., the performance of the CFS when used to 
predict 1-year mortality in 307 older hospitalized patients exceeded that of the FI, 
several other frailty measurement tools, and also measures of co-morbidity burden 
and dependency.140, 141  
The use of the CFS to identify older people who are approaching end-of-life 
is appealing because of its ease of use, good face validity and strong predictive 
performance. However, it is a graded tool designed to identify people who are at 
risk of a range of clinical outcomes (e.g. falls, dependency, institutionalization, 
complications related to invasive procedures etc.) in addition to risk of death. 
Successive scores on the scale are defined in terms of increasing disability and this 
may be a limitation if it is to be used to identify people approaching end-of-life. 
Longitudinal studies indicate that approximately half of all disability develops 
slowly and progressively in association with advancing age and severity of disease; 
the remainder develops rapidly in association with acute events such as stroke or 
trauma.142 A patient who develops acute severe disability due to trauma may be 
relatively stable in other physiological systems and therefore may have a low short-











1.3 OPERATIONALIZING DEPRESCRIBING FOR OLDER PEOPLE 
APPROACHING END OF LIFE 
1.3.1 Identifying medications to be deprescribed 
In addition to NNT, Holmes et al. suggest incorporating time to benefit (TTB) and 
time to harm (TTH) data into deprescribing decisions.143 TTB refers to the time 
that a statistically significant benefit was observed in trials of people receiving a 
particular drug compared to an appropriate control group.143 Similarly, TTH is the 
time period that elapses before a statistically significant adverse effect of a 
treatment occurs in the treatment group compared to the control group.143 Using all 
this information for any particular drug and comparing it with an estimate of the 
patient’s remaining life expectancy, the authors postulate that a better estimate of 
net benefit (or net harm) can be made.143 The approach has clear limitations: firstly, 
drug data are derived from trials that generally exclude older patients approaching 
end-of-life and therefore may have limited applicability;21 secondly, as discussed, 
estimates of remaining life expectancy are commonly inaccurate;114-116 thirdly, the 
approach is likely to be time-consuming in a clinical setting. In light of these 
complexities, several tools have been developed in recent years to support 
clinicians with deprescribing decisions in older people approaching end of life. 
These tools can broadly be categorized as implicit (judgement-based) or explicit 
(criterion-based). 
The two most prominent implicit deprescribing tools in the medical 
literature are the Geriatric-Palliative algorithm (Figure 1.4)144 and the 
deprescribing algorithm proposed by Scott et al. (Figure 1.5).145 Both tools require 
the user to answer a series of questions about each individual medication in the 
patient’s drug regimen. While comprehensive and patient-centred, the outcome of 
applying such algorithms will depend on the knowledge, experience and attitudes 
49 
 
of the user. Judgement is required: the user is not provided with resources or 
decision aids to estimate treatment benefit-harm trade-offs in individual patients.  
The use of implicit medication assessment tools such as these, in general, is time-
consuming, and is likely to result in variations in practice between physicians; for 
these reasons integration into routine clinical practice has been very limited.146  
 



















An evidence-based consensus exists for using the drug 
for the indication given in its current dosing rate, in 
the patient’s age group and disability level, and the 
benefit outweighs all possible known adverse effects 
Indication seems valid and relevant in this 
patient’s age group and disability level 
Do the known possible adverse reactions 
of the drug outweigh possible benefit in 
old, disabled patients? 
Any adverse symptoms or signs that may 
be related to the drug? 
Another drug that may be superior to the 
one in question? 













































Figure 1.5: Scott et al.’s deprescribing algorithm. Each medication is 





















STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail adults with 
limited life expectancy; figure 1.6) criteria were published in 2017 and consist of 
27 mostly explicit indicators to assist physicians with deprescribing decisions in 
1. No benefit 
Significant toxicity OR no indication OR obvious 
contraindication OR cascade prescribing? 
 
No 
             2. Harm outweighs benefit 
Adverse effects outweigh symptomatic effect or 
potential future benefits? 
No 
            3. Symptom or disease drugs 
Symptoms stable or non-existent? 
No 
                  4. Preventive drugs 
Potential benefit unlikely to be realized because of 





Continue drug therapy 
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frail older individuals with poor 1 year survival prognosis.147 The criteria were 
created following a literature appraisal and two rounds of Delphi consensus 
validation involving 17 panellists with expertise in geriatric medicine, clinical 
pharmacology, palliative medicine, general practice and psychiatry.  Of the 27 
indicators, 26 are explicit (i.e. clearly defined statements highlighting the 
potentially inappropriate use of particular drug/ drug classes in a particular clinical 
situation) and one is implicit (i.e. Criterion A2: Stop any drug without a clear 
clinical indication). The criteria are organized according to physiological systems 
and are designed to be used by physicians of all disciplines who commonly provide 
care for frailer older people. The inter-rater reliability of STOPPFrail in a recent 
study was shown to be substantial (mean kappa 0.76 ± 0.6) when evaluated among 
general practitioners, geriatricians and palliative care physicians using theoretical 
test cases.148 This suggests that STOPPFrail-guided deprescribing, as an 
intervention, is likely to be reproducible in different settings. However, 
STOPPFrail has important limitations. Firstly, it is unclear how prevalent the 
prescribing of the listed medications is amongst older frailer adults and whether 
discontinuation would result in important patient-related outcomes. Secondly, the 
user is not prompted to explore symptoms such as poor appetite, nausea, altered 
bowel habit, sedation and gait disturbance, which could represent the adverse 
effects of prescribed drugs. Finally, shared decision making is not emphasized in 







Figure 1.6: STOPPFrail Criteria 
STOPPFrail is a list of potentially 
inappropriate prescribing 
indicators designed to assist physicians with 
stopping such medications in older patients 
(≥ 65 years) who meet ALL of the criteria 
listed below: 
1) End-stage irreversible 
pathology 
2) Poor one-year survival 
prognosis 
3) Severe functional or severe 
cognitive impairment or 
both 
4) Symptom control is the 
priority rather than 
prevention of disease 
progression 
The decision to prescribe/not prescribe 
medications to the patient, should also be 
influenced by the following issues: 
1) Drug adherence/compliance is 
difficult 
2) Administration of the 
medication is challenging 
3) Monitoring of the medication 
effect is challenging 
4) Drug adherence/ compliance is 
difficult 
Section A: General 
A1: Any drug that the patient persistently fails 
to take or tolerate despite adequate education 
and consideration of all appropriate 
formulations. 
A2: Any drug without clear clinical indication. 
 
Section B: Cardiology system 
B1. Lipid lowering therapies (statins, 
ezetimibe, bile acid sequestrants, fibrates, 
nicotinic acid and acipimox) 
These medications need to be prescribed for a 
long duration to be of benefit. For short-term 
use, the risk of adverse drug events (ADEs) 
outweighs the potential benefits  
B2. Alpha-blockers for hypertension 
Stringent blood pressure control is not required 
in very frail older people. Alpha blockers in 
particular can cause marked vasodilatation, 
which can result in marked postural 
hypotension, falls and injuries 
 
Section C: Coagulation system 
C1: Anti-platelets 
Avoid anti-platelet agents for primary (as 
distinct from secondary) cardiovascular 
prevention (no evidence of benefit) 
 
Section D: Central Nervous System 
D1. Neuroleptic antipsychotics 
Aim to reduce dose and discontinue these drugs 
in patients taking them for longer than 12 weeks 
if there are no current clinical features of 
behavioural and psychiatric symptoms of 
dementia (BPSD)  
D2: Memantine 
Discontinue and monitor in patients with 
moderate to severe dementia, unless 
memantine has clearly improved BPSD 
(specifically in frail patients who meet the 
criteria above) 
Section G: Musculoskeletal System 
G1: Calcium supplementation 
Unlikely to be of any benefit in the short term 
G2: Anti-resorptive/bone anabolic drugs FOR 
OSTEOPOROSIS (bisphosphonates, strontium, 
teriparatide, denosumab) 
G3. Selective Estrogen Receptor Modulators 
(SERMs) for osteoporosis 
Benefits unlikely to be achieved within 1 year, 
increased short-intermediate term risk of 
associated ADEs particularly venous 
thromboembolism and stroke  
G4. Long-term oral NSAIDs 
 Increased risk of side effects (peptic ulcer disease, 
bleeding, worsening heart failure etc.) when taken 
regularly for ≥ 2 months  
G5. Long-term oral steroids 
Increased risk of side effects (peptic ulcer disease 
etc.) when taken regularly for ≥ 2 months. 
Consider careful dose reduction and 
discontinuation  
 
Section H: Urogenital System 
H1. 5-alpha reductase inhibitors 
No benefit with long term urinary bladder 
catheterisation  
H2. Alpha blockers 
No benefit with long term urinary bladder 
catheterisation 
H3. Muscarinic antagonists 
No benefit with long term urinary bladder 
catheterisation, unless clear history of painful 
detrusor hyperactivity  
 
Section I: Endocrine System 
I1. Diabetic oral agents 
Aim for monotherapy. Target of HbA1c 
<8%/64mmol/mol. Stringent glycaemic control is 
unnecessary  




1.3.2 Shared decision-making  
Shared decision making involves the sharing of information between the patient 
and physician, building consensus about preferred treatments and their rationale, 
and then reaching agreement on the treatment to be implemented.8 Patient 
involvement in healthcare decisions is a key component of patient-centred care.149 
When patients engage in shared decision making, they feel more knowledgeable, 
better informed and clearer about their values.150 Furthermore, patients are more 
likely to choose more conservative options when they engage in shared decision 
making.150 There is also evidence that patients prefer to participate in medical 
decision making. A recent systematic review of peer reviewed journal articles 
Section E: Gastrointestinal System 
E1. Proton Pump Inhibitors 
Proton Pump Inhibitors at full therapeutic dose 
≥ 8/52, unless persistent dyspeptic symptoms at 
lower maintenance dose  
E2: H2 receptor antagonist 
H2 receptor antagonist at full therapeutic dose 
for ≥ 8/52, unless persistent dyspeptic 
symptoms at lower maintenance dose  
E3. Gastrointestinal antispasmodics 
Regular daily prescription of gastrointestinal 
antispasmodics agents unless the patient has 
frequent relapse of colic symptoms because of 
high risk of anti-cholinergic side effects  
 
Section F: Respiratory System 
F1. Theophylline.  
This drug has a narrow therapeutic index, 
requires monitoring of serum levels and 
interacts with other commonly prescribed drugs 
putting patients at an increased risk of ADEs  
F2. Leukotriene antagonists (Montelukast, 
Zafirlukast) 
These drugs have no proven role in COPD, they 
are indicated only in asthma (50) 
Stop where prescribed only for prevention and 
treatment of diabetic nephropathy. There is no 
clear benefit in older people with advanced frailty 
with poor survival prognosis  
I3. Angiotensin Receptor Blockers (ARBs) 
Stop where prescribed only for prevention and 
treatment of diabetic nephropathy. There is no 
clear benefit in older people with advanced frailty 
with poor survival prognosis  
I4. Systemic oestrogens for menopausal 
symptoms  
Increases risk of stroke and VTE disease. 
Discontinue and only consider recommencing if 
recurrence of symptoms  
 
Section J: Miscellaneous 
J1. Multi-vitamin combination supplements 
Discontinue when prescribed for prophylaxis 
rather than treatment 
J2. Nutritional supplements (other than 
vitamins) 
Discontinue when prescribed for prophylaxis 
rather than treatment  
J3: Prophylactic Antibiotics 
No firm evidence for prophylactic antibiotics to 
prevent recurrent cellulitis or UTIs  
Disclaimer (STOPPFrail) 
Whilst every effort has been made to ensure that the potentially inappropriate prescribing 
criteria listed in STOPPFrail are accurate and evidence-based, it is emphasized that the final 
decision to avoid or initiate any drug referred to in these criteria rests entirely with the 
prescriber. It is also to be noted that the evidence base underlying certain criteria in 
STOPPFrail may change after the time of publication of these criteria. Therefore, it is advisable 
that prescribing decisions should take account of current published evidence in support of or 
against the use of drugs or drug classes described in STOPPFrail. 
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found that, in 63% of articles most patients expressed a wish to actively participate 
in decisions around their treatment.151 
Qualitative studies have indicated that clinicians are often reluctant to 
initiate discussions about deprescribing with older people, believing that they 
would resist having their medications discontinued or that they would interpret 
deprescribing as withdrawing of care or “giving up” on active treatment.152, 153  
These perceptions, however, have not been borne out in patient-focussed 
research.154, 155 Reeve et al.  recently examined attitudes of older people towards 
deprescribing in a nationally representative sample of Medicare beneficiaries in the 
United States.154 In this study, 92% of people indicated a willingness to discontinue 
one or more of their medications if their physician said it was possible and 
appropriate to do so, and 66% reported a desire to reduce the number of 
medications that they were taking. The greatest predictor of willingness to 
deprescribe was the taking 6 or more daily medications.154 The results are 
important for clinical decision-making and suggest that physicians can be reassured 
that broaching the topic of deprescribing with their older patients is generally 
acceptable to them.  
In that same study, Reeve et al.  suggested that clinicians could initiate 
discussions about deprescribing by explaining that “benefits and risks (of 
medications) can change over time” and that, therefore, some long-term 
medications may no longer be necessary in some older patients.154  For patients 
approaching end of life however, deprescribing decisions may form part of a wider 
discussion around goals of care. Indeed, communication around goals of care is a 
central element in ensuring that patients receive the care that they want, in 
alleviating anxiety, and in supporting patients’ families.156-158 While patients expect 
55 
 
their physician to initiate discussions about goals of care and end of life 
preferences,159 in reality physicians often do not approach these discussions until 
late in the course of older patients’ final illness. Mack et al., in a large prospective 
cohort study of patients with metastatic colorectal and lung cancer, found that the 
initial conversations around end-of-life care took place an average of 33 days 
before death.160 These findings are significant because  patients who are not aware 
that they are approaching end of life may overuse treatments of limited benefit (i.e. 
preventive medications) and underuse services that support quality of life (e.g. 
specialist palliative care, psychosocial and spiritual support).161, 162  
Decisions about medications represent just one aspect of the many 
decisions that patients and their physicians face when they discuss goals of care 
and usually other aspects of the discussion take priority. For this reason, a focus on 
the patient’s values, such as whether the patient favours a primary focus on 
extending life or a primary focus on palliation may be more worthwhile than 
concentrating on the merits of individual therapies.162, 163 Some patients may desire 
more detailed information and, in general, the discussion should be tailored to the 
patient’s level of knowledge about their overall condition and information 
preferences.162 While withdrawal of certain treatments may be recommended, 






1.4  EVIDENCE OF EFFICACY FOR DEPRESCRIBING 
 
Two recent systematic reviews examined the impact of deprescribing interventions 
on prescribing and clinical outcomes.165, 166 Thillainadesan et al.165 focussed on 
older hospitalized patients (i.e. ≥65 years old) while Dills et al.166 included adult 
patients aged ≥18 years old in outpatient, assisted living, nursing home and acute 
care settings. Only RCTs were included. Both reviews concluded that 
deprescribing interventions can reduce medication burden but evidence of a 
positive impact on important clinical outcomes such as ADRs, falls, 
rehospitalisation, quality of life and mortality is weak and of low quality.  
There is very limited high-quality evidence evaluating the impact of 
deprescribing specifically in older people approaching end of life. Kutner et al., in 
a multicentre unblinded randomized trial, examined the safety and clinical 
implications of discontinuing statin drugs for patients with advanced disease and 
limited prognosis.167 The ‘surprise question’,119 as well as evidence of recent 
functional decline, was used to identify eligible patients. In total, 381 patients were 
included in the study. There were no significant difference in mortality or 
cardiovascular events between the intervention and control group at 60 days but 
quality of life (QoL) was better in the patients who discontinued statin therapy. 
While the difference in QoL scores was statistically significant, the difference was 
small (mean McGill QoL score 7.11 versus 6.85; p = 0.04) and, therefore, of 
uncertain clinical relevance.167  
At the time of writing this thesis, there are no other RCTs of deprescribing 
interventions involving older people approaching end of life. However, various 
medication optimization interventions have been tested in nursing home residents. 
Because nursing home residents usually represent an older, frailer population and 
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because the median time from admission to a nursing home to death generally 
ranges from 5 to 15 months, these data are likely to be relevant.168, 169 A 2016 
Cochrane review evaluated RCTs of medication optimization interventions in 
nursing home residents.170 Overall, 12 studies involving 10,953 residents in 355 
nursing homes in ten countries were included. In five of the studies, interventions 
resulted in improvements in measures of prescribing quality. Overall, however, 
there was no clear evidence of benefit with respect to reducing adverse drug 
reactions or mortality.170 
Most interventions in these studies involved a pharmacist and/or a 
physician conducting a formal medication review. Identifying deprescribing 
targets, as discussed, is complex and healthcare professionals will vary in their 
assessment of the importance and appropriateness of medications.171, 172 Therefore, 
structured interventions, which can be reproduced in different settings, are 
preferable.173 The Geriatric –Palliative algorithm and Scott’s algorithm described 
earlier have both been evaluated in the nursing home setting: these studies are 
summarized in Table 1.5.174, 175 While both interventions significantly reduced the 
number of medications in intervention patients, the Geriatric-Palliative algorithm 
was also associated with a significant reduction in mortality and acute hospital 
transfers.175 However, these outcomes should be interpreted with caution. This was 
not a randomized controlled trial and the process of allocating participants to the 







Table 1.5:  Characteristics of studies involving Scott’s deprescribing algorithm 
and the Geriatric-Palliative algorithm 
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Older people with multimorbidity and frailty are amongst the highest consumers of 
prescription medications. While it may be possible to justify individual drugs on 
the basis of medical indication, the cumulative effect of multiple medications may 
result in net harm to the patient. The pharmacotherapy evidence base has serious 
limitations when applied to frail multi-morbid older people and, as older people 
enter the final phase of life, polypharmacy may be associated with unnecessary 
burden, adverse drug reactions and increased healthcare costs.  
An acute hospital admission in an older person often signals a change in 
survival trajectory and therefore could serve as a trigger to review medications and 
goals of care. As discussed, approximately one-in-four older adults admitted to 
hospital with acute illness will be deceased within a year. 109, 110 The challenge for 
clinicians is to distinguish between those who are likely to regain health and those 
who are in irreversible decline. In this regard, the HOMR model appears promising 
but requires independent validation in an older hospitalized sample.  
The last year of life for many older people is a period of high symptom 
burden with frequent and prolonged hospital admissions. It follows then that the 
last year of life is also likely to be a period of high medication burden, especially 
during periods of acute illness. To date, this has not been demonstrated in any 
clinical study. If shown to be true, it reinforces the value of conducting a formal 
medication review for frail older people when they present to hospital with acute 
illness. The goal of such a review would be to strike a balance between high quality 
evidence-based care and burdensome and potentially harmful polypharmacy. 
Identifying deprescribing targets is challenging, especially in multimorbid 
older adults who are at high risk of clinical deterioration. The use of explicit 
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deprescribing criteria (e.g. STOPPFrail) is appealing because it could simplify the 
process of deprescribing for physicians of different disciplines, who do not 
necessarily have expertise in geriatric pharmacotherapy. However, at this point, it 
is unclear whether STOPPFrail criteria are comprehensive enough to be considered 
a reasonable alternative to specialist medication review. In addition, up to now, 
there have been no randomized controlled trials using STOPPFrail criteria as an 
intervention tool. Therefore, it is uncertain whether application of STOPPFrail 
criteria can reduce medication burden for frail older people without adversely 
affecting clinical outcomes.  
In subsequent chapters, through a series of original studies, I will attempt to 



































Predicting one-year risk of death in older hospitalized patients: external 






















An important principle when caring for an older person with frailty and multi-
morbidity is to align treatments and interventions to the patient’s condition, 
preferences, and prognosis.176 When life expectancy is limited, interventions to 
optimize quality of life may be prioritized over invasive procedures and potentially 
futile treatments.  Patient-centred discussions about goals of care and, indeed, 
decisions about the deprescribing of long-term medications, are often deferred in 
frailer older patients because of physician discomfort and lack of confidence in 
making accurate prognostic assessments.177, 178 As discussed in Chapter 1, 
physicians commonly over-estimate remaining life expectancy in their patients.114, 
116 It follows then that they may unnecessarily treat their patients with potentially 
futile medications. An accurate estimate of prognosis, especially when risk of death 
is high, could inform and motivate discussions between physicians and their 
patients about values, priorities, and therapeutic goals. 
The Hospital patient One-year Mortality Risk (HOMR) model has recently 
been shown to accurately predict one-year mortality risk at the time of hospital 
admission for adult (i.e.  18 years), non-psychiatric patients.125, 126 It is comprised 
of covariates that include demographics, co-morbidities, severity of acute illness, 
and recent acute hospital care utilization (Figure 2.1). These covariates are 
determined at hospital admission using health administrative data. Over 3 million 
patients aged 18 or older were included in the validation studies in Ontario and 
Alberta (Canada), and Boston (United States).125, 126 The HOMR model had a very 
high discriminative performance (an area under the receiver operating 
characteristic (ROC) curve of 0.89 -0.92) and there was a less than 1% difference 
between the observed and expected percentages of deceased patients at 1 year.  
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Figure 2.1:  Covariates used to calculate a patient’s Hospital-patient One-year 

























Diagnostic Risk Score 
See Appendix 2 
Charlson Comorbidity Index score 
Diagnosis Points Diagnosis Points 
Myocardial infarction 1 Diabetes with chronic complications 2 
Heart failure 2 Hemi- or paraplegia 1 
Peripheral vascular disease 1 Renal disease 3 
Cerebrovascular disease 1 Nonmetastatic cancer 2 
Dementia 3 Moderate to severe liver disease 4 
Chronic respiratory disease 2 Metastatic cancer 6 
Mild liver disease 2 HIV infection 4 




Points  Sex Points 
0 0  No 0 
1 3  Yes 1 
2 4    
≥3 5    
Charlson Comorbidity Index score: Age x comorbidity 
Age, yr. 0 1 2 3 4 5 ≥6 
20-24.9 0 3 5 7 8 9 10 
25-29.9 2 5 7 9 10 11 11 
30-34.9 4 7 9 11 12 12 13 
35-39.9 7 9 11 12 13 14 15 
40-44.9 8 11 13 14 15 15 16 
45-49.9 10 13 14 15 16 17 17 
50-54.9 12 14 16 17 17 18 18 
55-59.9 14 16 17 18 19 19 17 
60-64.9 15 17 18 19 20 20 18 
65-69.9 17 19 20 21 21 22 20 
70-74.9 18 20 21 22 22 23 21 
75-79.9 20 21 22 23 23 24 22 
80-84.9 21 23 23 24 24 25 25 
85-89.9 23 24 25 25 25 26 26 
90-94.9 24 25 26 26 26 27 27 
≥95 25 26 27 27 27 28 28 
Living status/ admission urgency x admissions by ambulance 
                                                           No. of admissions by ambulance 
 0 1 2 ≥3 
Living status     
   Home, independent 0 0 0 0 
   Rehabilitation facility 3 3 2 2 
   Home with home care 4 3 3 3 
   Nursing home 4 4 4 3 
   Chronic care hospital 8 6 5 5 
Admission urgency     
    Elective 0 0 0 0 
    ED, no ambulance 3 1 0 0 





ED visits  





























































The HOMR model’s performance exceeds that of other similar prognostic models.  
However, it has not been validated in an exclusively older hospitalized patient 
population. In addition, like many published prognostic models, the HOMR model 
has yet to be externally validated by investigators who were not involved in its 
development. This is important because before a model can be applied in clinical 
practice with confidence, it needs to be tested in new patients and in different 
geographical regions.179 The aim of this study was to evaluate the performance of 
the HOMR model in a population of older hospitalized patients in a large teaching 




2.2.1 Data collection 
The HOMR model was retrospectively applied to all hospitalized patients aged 65 
years or older that were under the care of the specialist geriatric medicine service in 
Cork University Hospital from January 1st 2013 to March 6th 2015.  When patients 
were admitted more than once during that period, a single hospital admission was 
chosen at random as the index hospitalization. Most of the information required to 
calculate the HOMR model was obtained using administrative data from the 
Hospital In-Patient Enquiry system (HIPE -a national database of coded discharge 
summaries). The International Statistical Classification of Diseases and Related 
Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), 
Australian Classification of Health Interventions (ACHI) and Australian Coding 
Standards (ACS) apply to all activity coded in HIPE in Ireland.180  Details about 
home supports prior to admission as well as provision of home oxygen therapy, 
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which are not routinely collected by administration staff in Ireland, were obtained 
from the consultant geriatrician hospital discharge reports. When information was 
missing from these sources, the patients’ medical records were reviewed. Covariate 
values were determined independently by two researchers with discrepancies 
resolved through consensus.  
Deaths within one year of hospital admission were determined by accessing 
the hospital clinical information system, an online death notification system 
(https://www.RIP.ie), the Births, Deaths and Marriages Registry Office in Cork 
City, and, if required, by contacting the patient’s general practitioner. Unlike the 
initial HOMR derivation and validation studies, patients who died during the index 
hospital admission were not included. There were two reasons for this. Firstly, 
geriatrician discharge reports were used to obtain information about home supports 
for the HOMR model, and these details were generally not included when the 
patient died during hospitalization. Secondly, the value of the predictive model, for 
the present project, is to calculate 1-year mortality risk after the acute hospital 
episode. Predicting in-hospital deaths largely depends on specific clinical factors.  
 
2.2.2 Statistical analysis  
A sample size that results in at least 100 events, and preferably 200 or more events, 
is recommended to externally validate a prognostic model.181 It was estimated that 
one-year mortality after hospital discharge would very likely exceed 15%,109,182 and 
on that basis I calculated that a sample size of 1400 patients would be required. 
To validate the HOMR model, the linear predictor for each patient was calculated 
based on the coefficient values provided in Appendix E of the original HOMR 
model development study.125 The HOMR model was then evaluated in terms of its 
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overall performance, discrimination and calibration. The model’s overall 
performance was evaluated using the Brier score, rescaled to range from 0 to 1, 
with higher values indicating better performance.183 Discrimination, which refers to 
how well the model distinguishes those with the outcome from those without the 
outcome (i.e. death in this case), was measured using the concordance (c) statistic. 
Calibration refers to the agreement between observed outcomes and predicted 
outcomes and is usually displayed using a calibration plot. For a perfectly 
calibrated model, the plotted values should lie on a 45˚ straight line.184 In addition 
to calibration plots, the maximum and average difference in predicted versus loess-
calibrated probabilities (Emax and Eavg) are reported.185 Finally, bootstrapped 
95% confidence intervals for these metrics are reported, based on 500 resampled 
replicates.186 
To recalibrate the HOMR Model, the procedure described by Vergouwe et 
al. was followed and three additional logistic regression models were estimated.187 
The first additional model included the HOMR linear predictor, with its coefficient 
set to equal 1, and a freely estimated intercept (Recalibration in the Large). The 
second model then allowed the coefficient on the HOMR linear predictor to be 
freely estimated (Logistic Recalibration). The third model included the complete 
set of variables used in the HOMR model, including the same transformations and 
interactions, and allowed their respective coefficients to be freely estimated (Model 
Revision). The performance of each of these models was assessed using the same 
metrics used to validate the original HOMR model. In addition, optimism corrected 
c-statistic and shrinkage factor were estimated for the Model Revision using 
bootstrapping (with 500 re-sampled replicates). All analyses were conducted using 
the R language for statistical computing, 188 version 3.4.3 (2017-11-30). Expert 
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statistical support for this study was provided by Dr. Darren Dahly, senior lecturer 




2.3.1 Characteristics of study population 
Between January 1st 2013 and March 6th 2015, 1654 individual patients aged 65 
year or older were hospitalized under the care of the specialist geriatric medicine 
service in Cork University Hospital. Of these, 206 patients (12.4%) died during the 
index hospitalization and therefore were not included in the analysis. After 
removing 39 patients with missing outcome data (2.7%), a final cohort of 1409 
patients were analysed. Of these, 259 (18.4%) died within 1 year of admission to 
hospital. The median age of the study patients was 80 years (interquartile range 74 
-85), two thirds were living independently prior to their hospital admission, and 
94.5% of patients were admitted through the emergency department. The baseline 
characteristics of the study participants are summarized in Table 2.1. 
 
Table 2.1: Baseline characteristics of study participants (and how they compare 
to original derivation cohort125). 
 
Variable Mean SD Median 
[IQR] 
(Min, Max) HOMR 
derivation 
cohort 
Sex     
Female 800 (56.8%)   61.8% 
Male 609 (43.2%)   38.2% 
Age 79.3 ± 7.4 80 (74, 85) (65, 101) 59 (IQR 37 -
75) 
Living Status*     
Independent 933 (66.2%)   83% 
Rehabilitation Unit 33 (2.3%)   0.2% 
Homecare 295 (20.9%)   12.1% 
Nursing Home 148 (10.5%)   4.5% 
Urgency of admission     
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Elective 78 (5.5%)   47.4% 
ED without Ambulance 498 (35.3%)   25.7% 
ED with Ambulance 833 (59.1%)   26.9% 
Number of ambulance 
transfers** 
0.3 ± 0.7 0 (0, 0) (0, 5) N/A 
Admitting Service***     




  31.4% 
General Surgery 3 (0.2%)   11% 
Cardiology 17 (1.2%)   6.4% 
Orthopedics 8 (0.6%)   8.4% 
Gastroenterology/Nephrology/ 
Neurology 
16 (1.1%)   4.9% 
ICU admission (directly from 
emergency department) 
3 (0.2%)   7.4% 
Home O2* 0   2.3% 
ED Visits**     
0 828 (58.8%)   55.1% 
1 581 (41.2%)   44.9% 
Urgent readmission within 30 
days 
131 (9.3%)   4.5% 
DRS -1.9 ± 4.8 0 (-1, 0) (-22, 9) N/A 
CCI****     
0 23.3%   57.8% 
1-2 34.2%   21.7% 
3 42.5%   20.5% 
Legend: CCI =Charlson Comorbidity Index; DRS = Diagnostic Risk Score; ED = emergency 
department; HOMR = Hospital-patient One-year Mortality Risk; ICU = intensive care unit; 
IQR = interquartile range; N/A = not available; SD = standard deviation. *Prior to index 
hospitalization. ** In 12 months prior to index hospitalization.*** All patients, after 
hospital admission, were under the care of the specialist geriatric medicine service. **** 
Not adjusted for patient age.  
 
 
2.3.2 HOMR model external validation 
When the HOMR model was applied directly to the sample of 1409 older patients, 
it showed good discrimination (c statistic =0.78). Calibration, however, was poor 
(see Figure 2.2 for calibration plot) with the model consistently over-estimating 







Figure 2.2: Calibration plot of the unadjusted Hospital patient One-Year 





Table 2.2:  Performance of the unadjusted and updated Hospital patient One-
Year Mortality Risk (HOMR) models. 
 





Intercept 0 -0.42 -0.43 - 
Slope 1 1 0.99 - 
Residual deviance 1139.96 1107.76 1107.73 1046.55 
Df 1409 1408 1407 1389 
LRT Chi sq p-value - <0.001 0.85 - 
Brier score 
(rescaled) 
0.15 (0.1 to 0.21)* 0.19 (0.13 to 0.25) 0.19 (0.13 to 0.26) 0.23 (0.18 to 0.31) 
Emax 0.103 (0.085 to 
0.146) 
0.111 (0.03 to 
0.225) 
0.121 (0.03 to 
0.236) 
0.017 (0.016 to 0.094) 
Eavg 0.058 (0.046 to 
0.072) 
0.016 (0.01 to 
0.028) 
0.017 (0.009 to 
0.029) 
0.008 (0.005 to 0.016) 
c-statistic 0.78 (0.76 to 0.81) 0.78 (0.75 to 0.81) 0.78 (0.76 to 0.81) 0.82 (0.8 to 0.85) 
* Bootstrapped 95% confidence intervals 
Legend: Df = degrees of freedom; LRT = likelihood ratio test; Emax = maximum absolute 
difference in predicted and calibrated probabilities; Eavg = average absolute difference in predicted 









2.3.3 Performance of updated HOMR model 
All three updating methods improved calibration over the original model (Figure 
2.3).  Recalibration in the Large resulted in a lower intercept (-0.42; see Table 2.2) 
and a significant improvement in model fit over the HOMR model (likelihood ratio 
test [LRT] Chi-square p value= <0.001). Logistic Recalibration did not lead to 
additional improvements in model fit (LRT Chi-square p value = 0.85), with a 
recalibration slope of 0.99 (i.e. close to 1). The Brier score and Eavg were 
improved by recalibration (Table 2.2). Calibration plots for Recalibration in the 
Large (which is virtually identical to the plot for Logistic Recalibration) and Model 
Revision are shown in Figure 2.3. In addition to improving calibration, Model 
Revision also improved discrimination (c statistic =0.82) which indicates that the 
relationship of the predictors and the outcome is different in our older patient 
sample. The optimism corrected c-statistic for the Model Revision was 0.8, and the 
shrinkage factor was 0.91, indicating some overfit. The re-estimated HOMR 
model, with regression coefficients, is shown in Table 2.3.  
 
Figure 2.3: Calibration plots of the updated Hospital patient One-year Mortality 




Table 2.3: HOMR Model Revision with regression coefficients 
Legend:  CCI = Charlson Comorbity Index; DRS = diagnostic risk score; ED = emergency 




This study provides information about the performance of the HOMR model in 
new patients, in a different geographical region, when validated by investigators 
Variable 1-year post-hospitalization 
mortality 
DRS 0.11 (0.07, 0.15) 
sqrt (Age) 1.45 (0.60, 2.30) 
Male (vs Female) 0.44 (0.12, 0.77) 
Rehab 0.82 (-1.75, 3.38) 
Homecare 1.16 (-0.24, 2.56) 
Nursing Home 1.56 (0.13, 2.99) 
log (CCI) 2.78 (-2.76, 8.33) 
sqrt (Ed visits in the previous year + 1) 0.16 (-1.23, 1.55) 
1/ (Admissions by ambulance in previous year 
+1) 
-2.03 (-4.75, 0.70) 
Other (vs General Medicine) -0.68 (-1.58, 0.22) 
ED w/o Ambulance -0.83 (-3.16, 1.49) 
ED w/Ambulance -1.21 (-3.41, 0.98) 
Urgent readmission 0.60 (0.07, 1.12) 
Sqrt (Age) log (CCI) -0.23 (-0.84, 0.38) 
Rehab 1/ (Admissions by ambulance in previous 
year +1) 
-0.15 (-3.66, 3.36) 
Homecare 1/ (Admissions by ambulance in 
previous year +1) 
0.31 (-1.23, 1.85) 
Nursing Home 1/ (Admissions by ambulance in 
previous year +1) 
-0.20 (-1.91, 1.52) 
ED w/o Ambulance 1/ (Admissions by 
ambulance in previous year +1) 
1.04 (-1.73, 3.81) 
ED w/Ambulance 1/ (Admissions by ambulance 
in previous year +1) 
1.91 (-0.71, 4.53) 
Intercept -14.79 (-22.86, -6.72) 
Observations 1,409 
Log Likelihood -523.28 
Akaike Information Criterion 1,086.55 
Note:  
1. Admitting service recoded to General Medicine vs Other, due to small cell 
sizes. ICU admission from the model was omitted as there were only 3 cases of 
this happening. Home O2 was omitted from the model since no patients in our 
sample were using it. 
2. One-year mortality risk for individual patients can be calculated with the 
formula: Risk = exp (linear predictor) / (1 + exp (linear predictor).  
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who were not involved in the model’s development. The highly discriminative 
performance reported in the initial validation studies was substantially attenuated in 
the heterogenous multi-morbid hospitalized older cohort of the present study and 
calibration was found to be poor with the model consistently overestimating 
mortality risk. The results illustrate the importance of testing seemingly accurate 
prediction models in target populations before applying them widely in routine 
practice.  
There are plausible reasons for the reduced predictive performance in this 
external validation study. Firstly, the patients in the present cohort were 
substantially older (median age was 80 years versus 59 years in the HOMR  
derivation cohort) and less likely to be living independently (66.3% versus 83%).125 
Secondly, unlike the initial validation studies, patients who died during their index 
hospital admission were excluded. This is likely to have had a significant impact on 
the HOMR-based mortality prediction because one of the HOMR covariates, the 
diagnostic risk score (see Appendix 2), quantifies risk of death based on specific 
admission diagnoses.  High diagnostic risk scores associated with diagnoses such 
as intracerebral haemorrhage and sepsis reflect high risk of death during 
hospitalization. This risk may diminish significantly when patients survive the 
initial days of their acute hospital episode. Thirdly, it is unclear whether the 
diagnostic risk scores, which were derived from a large population of adult patients 
of all ages, are weighted appropriately for older hospitalized patients. An admission 
diagnosis of syncope, for example, is assigned a diagnostic risk score of -9 which 
probably reflects its usually benign prognosis in younger adults. In contrast, 
syncope, in older adults, is associated with reduced survival.189 Finally, substantial 
differences in access to and organization of primary care services between North 
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America and Ireland may have had an important impact on covariates relating to 
recent acute hospital care utilization (i.e. ambulance transfers, emergency 
department visits, readmissions). 190, 191 
Our findings are not surprising: the accuracy of predictive models is often 
substantially lower in new patient populations compared to the accuracy found in 
patients of the development population.192 -194 Rather than simply reject the model, 
updating methods were used to try to improve performance of in our older patient 
cohort. Updating methods adjust the prediction model to new patients by 
combining valuable information captured in the original development study (a very 
large data set) with the information of the validation cohort.195 In this study, 
recalibration in the large (the simplest updating method where just one parameter 
of the original model [i.e. the intercept] is adjusted) substantially improved 
performance. While model revision resulted in further improvements, this more 
extensive updating method is less ideal because parameter estimates are 
redeveloped from the data of the validation set (a much smaller sample) and prior 
information from the larger derivation sample is neglected.195  
The performance of the recalibrated HOMR model compares favourably 
with other validated prognostic models for older hospitalized patients that were 
included in a 2012 systematic review by Yourman et al. 124, 194 -204 (Table 2.4). 
Indeed, the predictive performance of the recalibrated HOMR model exceeds that 
of some risk models used widely in routine clinical practice, such as the CHADS2-
VASc (c-statistic, 0.61)205 and HAS-BLED (c-statistic, 0.72)206 models. However, 
it is important to emphasize that the updated HOMR models, just like a newly 
developed model, require testing of their generalizability, as well as their impact on 
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clinician behaviour and patient outcomes, before either can be recommended for 
use in daily clinical practice.207  
 
Table 2.4: Summary of prognostic models used to predict mortality in 
hospitalized older patients. 
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geriatric service; 
model re-calibrated for 
validation sample) 
Legend: BISEP = Burden of Illness Score for Elderly Persons; CARING = cancer, ≥2 admissions, 
residence in a nursing home, intensive care unit admission with multiorgan failure, ≥2 noncancer 
hospice guidelines; HELP = Hospitalized Elderly Longitudinal Project; HOMR = Hospital patient 
One year Mortality Risk; MPI = Multidimensional Prognostic Index; SAFES = Sujet Agé Fragile—




With further revision, refinement and validation, it may be possible to 
optimize the performance of the HOMR model for older hospitalized patients. 
Even then, its impact on decision-making will need to be tested.207 Determining the 
threshold for deviating from the standard of care may be difficult: a 50% one-year 
risk of death for an individual patient is highly relevant; however, at the end of that 
particular year, the patient is as likely to be alive as deceased. Prognostic estimates, 
therefore, even when very accurate, may not necessarily enhance certainty when 
making difficult clinical decisions.208  
The HOMR model uses administrative data rather than specific clinical 
information (e.g.  severity of chronic disease) to calculate one-year mortality risk. 
In addition, social supports (i.e. requirement for home care, residence in a nursing 
home) are used as a surrogate for functional status. Like other prediction models 
that have been derived from large databases, the HOMR model provides 
information about the probability of an outcome for the “average patient” with a 
given set of predictors. It tells us very little about the individual patient and his or 
her needs. Therefore, it is questionable whether this reductionist approach can add 
value to the delivery of end-of-life care at an individual patient level.  
The present study has some limitations. Firstly, the HOMR model was 
applied and updated in a single medical centre where patients were cared for by 
specialist geriatricians. As discussed, this limits the generalizability of our findings 
and further validation in other centres is required. Secondly, we used the model 
differently to how it was originally designed by excluding patients who died during 
their index admission. However, we contend that the primary purpose of an 
accurate 1-year mortality prediction in a hospitalized patient would be to help 
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guide decision-making and care-planning after the acute episode when the patient’s 
condition has stabilized.  
In conclusion, the exceptionally accurate 1-year mortality predictive 
performance of the HOMR model, reported in the North American validation 
studies, was significantly attenuated in a cohort of older hospitalized patients in a 
large teaching hospital in Ireland. Nevertheless, the performance of the HOMR 
model in our older patient cohort was demonstrably good and compares favourably 
to other validated non-disease specific mortality prediction tools for application in 
older people. Updating methods improved performance of the HOMR model but 
further refinement, validation, as well as clinical impact studies will be required 































Drug consumption and futile prescriptions: an observational study of hospitalized 



















Large observational studies have shown that hospitalizations are frequent in the last 
year of life.104, 107, 108 Hospital physicians, therefore, have an opportunity to 
optimize medication regimens for older people with advanced frailty or end-stage 
chronic disease. This task involves tailoring treatments to the condition, 
preferences and prognosis of the individual patient.176 In the context of burdensome 
polypharmacy, symptom control often takes priority over achieving strict chronic 
disease targets or preventing future adverse health events. 
Many frail, multi-morbid older people may not have the benefit of a formal 
medication review while they are in hospital. Hospital physicians may not feel 
confident or competent with addressing potentially inappropriate polypharmacy or 
may believe that they are solely responsible for medicine management within their 
own particular specialty.209 Status quo bias (a preference for continuing with usual 
medications, especially if they have been in place for years) and fear of negative 
consequences such as symptom relapse, litigation, increased workload are other 
barriers to deprescribing.178, 210 
As discussed in Chapter 1, the STOPPFrail criteria (Figure 1.6) are an 
explicit list of 27 indicators to assist physicians with deprescribing decisions in 
frail older individuals with poor one year survival prognosis.147 As a deprescribing 
tool, STOPPFrail is concise, easy-to-use and designed to be used by clinicians of 
all disciplines who commonly provide care for older people.147 However, the 
relevance and potential applicability of the STOPPFrail list for older people 
hospitalized in the last year of life has not yet been studied. 
Accordingly, the aims of this study were: 
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1. To determine the prevalence of potentially inappropriate medications 
(PIMs), as defined by the STOPPFrail tool, in the discharge prescriptions of 
older adults hospitalized in the last year of life. 
2. To measure medication consumption by older people while in hospital in 
the last year of life. 
 
3.2 METHODS 
3.2.1 Study population 
We included people aged ≥ 65 years who were hospitalized for ≥ 2 days under 
general medical services in a major teaching hospital in the year prior to death. The 
Hospital In-Patient Enquiry system (a national database of coded discharge 
summaries) was used to identify patients discharged between January 2013 to 
December 2014. When patients were admitted more than once during this period, a 
single hospitalization was randomly chosen as the index hospitalization. Patients 
who died during their index hospital admission and those discharged to a hospice, 
presumably in the final stages of a terminal illness, were excluded because the 
primary end point was to measure the prevalence of STOPPFrail-defined PIMs at 
the time of discharge. Deaths within one year of hospitalization were determined 
by accessing the Hospital Information System and an online death notification 
system (https://www.RIP.ie). In total, 603 patients were eligible for inclusion. We 
estimated that 50% of patients would be prescribed PIMs at discharge. Using a 
precision of 5% and a 95% level of confidence, we calculated that a minimum 
sample of 384 patients would be required for this study (Figure 3.1). To ensure an 
adequate final sample size, a random sample of 434 was generated using a 
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randomization (RAND) function in Microsoft Excel©. The local Clinical Research 
Ethics Committee approved the study protocol (see Appendix x). 
3.2.2 Data collection 
A retrospective chart review was conducted on all study patients by a Geriatric 
Medicine trained physician (Dr. Denis Curtin) using a standardized data collection 
pro forma. The prevalence of STOPPFrail-defined PIMs was measured by 
accessing the discharge prescriptions from the patients’ index hospitalization. 
Disease burden and performance status at the time of hospital discharge were 
determined using the Charlson Co-morbidity Index (CCI)211, 212 and the Clinical 
Frailty Scale (CFS)139 respectively. The CFS is a 9-item scale and, in this study, we 
categorized patients into 2 groups: (i) those with scores of ≥ 7 (indicating severe 
frailty and/or terminal illness and therefore potentially eligible for the STOPPFrail 
tool) and (ii) those with scores < 7 (indicating full independence, mild or moderate 
frailty). Medication consumption was determined by reviewing inpatient 
medication administration records from all hospitalizations in the last year of life. 
Medications that were prescribed but not consumed were not included, nor were 
nutritional products, blood products or intravenous fluids. A single ingredient 
constituted one medicine. For combination products, each ingredient was included 
as one drug as long as that ingredient was available as a medicine in the British 
National Formulary.  
 
3.3 RESULTS 
3.3.1 Patient characteristics 
In total, 410 patients were included (24 patients were excluded because of missing 
data or because they were discharged to the care of community palliative services). 
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The principal characteristics of the decedents are summarized in Table 3.1. The 
mean age of patients was 80.8 years (standard deviation [SD] 7.9 years) and 49.3% 
were female. Polypharmacy was highly prevalent and the mean number of 
medications per patient at the time of hospital admission was 8.4 (SD 4.3). At the 
time of hospital discharge, 63.7% of patients were either severely frail or had an 
advanced terminal diagnosis (CFS ≥7).   
 
Table 3.1: Baseline characteristics of study population 
Variable    Total (n=410) 
Mean age (SD) at time of index hospitalization 80.8 (7.9) 
Female (%) 202 (49.3%) 
Median no. of days (IQR) between index 
hospitalization and death 
124 (47-225.5) 
Home status prior to index admission:     
       Independent 
    
139 (33.9%)  
       Home with home care 
198 (48.3%)  
       
       NH resident  
    
73 (17.8%) 
Discharge health/functional status: 
        





       CFS ≥7  
     
    
261 (63.7%) 
Mean number (SD) of admission medications 8.4 (4.3) 
Mean number (SD) of discharge medications 8.7 (4.2) 
Legend: CCI = Charlson co-morbidity index; CFS = Clinical Frailty Scale; IQR = 




3.3.2 Prevalence of STOPPFrail PIMs at hospital discharge 
The mean number of medications prescribed per patient did not change 
significantly from index hospital admission to discharge (8.4 [SD 4.3] versus 8.7 
[SD 4.2], p= 0.275). More than 80% of patients were prescribed at least one 
STOPPFrail-defined PIM in their discharge prescription and 34% had ≥ 3 PIMs 
prescribed (Table 3.2). The mean number of PIMs did not differ significantly 
between patients’ potentially eligible for STOPPFrail-guided deprescribing (CFS 
≥7) and those with less advanced stages of frailty (2.0 [SD 1.5] versus 1.8 [SD 1.4], 
p= 0.053). Full implementation of the STOPPFrail recommendations for those with 
polypharmacy (defined here as ≥ 5 long term medications) would have resulted in, 
on average, a 23% reduction in total medication burden. Lipid lowering 
medications, proton pump inhibitors, anti-psychotics and calcium supplements 
accounted for 59% of all STOPPFrail-defined PIMs (Table 3.3). 
 
Table 3.2: STOPPFrail-defined potentially inappropriate medications (PIMs) 
prescribed per patient at hospital discharge 
 
 Total 
Mean no. of PIMs per patient (SD) 1.95 (1.4) 
Mean no. of PIMs/patient (SD) in patients discharged ≥30 days 
from death 
1.97 (1.4) 
Mean no. of PIMs/patient (SD) in patients with CFS ≥7 2 (1.46) 
≥1 PIM per patient 81.5% 
≥3 PIMs per patient 34% 




Table 3.3: Most frequently encountered potentially inappropriate prescriptions 
according to STOPPFrail criteria in 410 patients. 
 
STOPPFrail Criteria n 
A1: Any drug that the patient persistently fails to take or 
tolerate 
8 
A2: Any drug without clear clinical indication 70 
B1: Lipid lowering therapies 147 
B2: Alpha-blockers for hypertension 6 
C1: Anti-platelets for primary cardiovascular prevention 15 
D1: Neuroleptic antipsychotics 48 
D2: Memantine 14 
E1: Proton Pump inhibitors 166 
E2: H2 receptor antagonists 3 
E3: Gastrointestinal antispasmodics 0 
F1: Theophylline 7 
F2: Leukotriene antagonists  5 
G1: Calcium supplementation 105 
G2: Anti-resorptive/ bone anabolic drugs 36 
G3: Selective Estrogen Receptor Modulators for osteoporosis 0 
G4: Long-term oral NSAIDs 1 
G5: Long-term oral steroids 31 
H1: 5-alpha reductase inhibitors with long-term bladder 
catheterisation 
0 
H2: Alpha blockers with long-term bladder catheterisation 1 
H3: Muscarinic antagonists with long-term bladder 
catheterisation 
0 
I1: Diabetic oral agents 24 
I2: ACE-inhibitors for diabetes 5 
I3: Angiotensin receptor blockers 0 
I4: Systemic oestrogens for menopausal symptoms 0 
J1: Multivitamin combination supplements 8 
J2: Nutritional supplements (other than vitamins) 84 





3.3.3 Drug consumption while in hospital in the last year of life 
 
In the year prior to death, the median number of days in hospital in this population 
of patients was 32 (interquartile range [IQR] 15-58). One-third of patients had 3 or 
more emergency department presentations in their last year. During all hospital 
stays in the last year of life, the mean number of individual medications consumed 
per patient was 23.8 (SD 10.1). One-in-six patients consumed ≥ 35 different 
medications (Table 3.4). Long-term preventive medications accounted for 9.5% of 
all medications consumed during hospitalization but 24.9% of medications 
prescribed at the time of hospital discharge.  
 
Table 3.4: Acute hospital care utilization and medication consumption in the 
last year of life 
Legend: IQR = interquartile range; LMWH= low molecular weight heparin; SD = 
standard deviation 
 
Variable Total  
Median bed days (IQR)  32 (15-59)  
Median hospital admissions (IQR) 2 (1.25 -3) 
Median emergency department episodes (IQR) 2 (1-3) 
≥ 30 Bed days  53.4%  
≥ 3 hospital admissions  43.4%  
≥ 3 emergency department episodes 34% 
No. of medications (SD) consumed during hospitalization 
 
 Mean (SD) 
 
≥ 25 medications  
 








Types of medications consumed during hospitalization: 
 
Disease/ symptom control 
 
Long-term preventive  
(i.e. anti-thrombotics, lipid-lowering agents, calcium, vitamin D, 
bisphosphonates, bone anabolic drugs) 
 














This is the first study of its kind using recently validated explicit deprescribing 
criteria designed for application in the frailest older people. Our data show that 
older people in their last year of life experience high levels of polypharmacy, a 
quarter of which includes long-term preventive therapies which are likely to be 
futile. Hospital physicians need to be able to recognize frailer older patients in their 
last year of life, and be prepared to deprescribe thoughtfully where appropriate, 
particularly long-term preventive drugs where benefit is unlikely to be realized. 
Symptoms at end-of-life are often complex and multifaceted. A large 
nationally representative longitudinal survey of adults in the United States reported 
that symptoms such as depression, confusion, dyspnoea, incontinence, fatigue, 
anorexia, and vomiting were all common in the last year of life.213 While 
improvements can usually be made regarding prescribing quality, high levels of 
medication consumption may be inevitable. This is important because the number 
of medications prescribed is the most important predictor of iatrogenic harm.214 
The challenge for the prescribing physician is to strike a balance between 
controlling multiple symptoms and minimizing the inherent risks of polypharmacy. 
Full implementation of STOPPFrail recommendations for hospitalized 
patients would have resulted in almost 1-in-4 long-term medications being 
discontinued.  The process of deprescribing must, of course, be individualized and 
patients’ preferences, clinical contextual factors, and the potential for adverse drug 
withdrawal events given due consideration.  As discussed in Chapter 1, many of 
other available deprescribing tools (e.g. Scott’s algorithm, 145 Geriatric –Palliative 
algorithm 144) are implicit and demand that the prescriber achieves a reasonable 
balance between the risks and benefits of each medication. The real-world 
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applicability of these methods to all but expert prescribers is doubtful and this 
likely explains why implicit deprescribing tools are rarely applied in routine 
clinical practice. The value of STOPPFrail is that it is explicit, concise, easy-to-use, 
and, as we have shown, highly relevant to the practice of hospital physicians.  
Recognizing when people are in the final phase of life is key to 
operationalizing deprescribing. As demonstrated in Chapter 2, the excellent 
performance of the Hospital-patient One-year Mortality Risk (HOMR) model in its 
initial validation studies was substantially attenuated when applied to a cohort of 
older hospitalized patients in a large teaching hospital in Ireland. Furthermore, 
Yourman and colleagues’ 2012 systematic review concluded that there was 
insufficient evidence to recommend application of any of the other published 
prognostic models for older adults.124 Therefore, physicians may need to rely on 
their clinical judgement and accept that there will always be uncertainty when 
making prognostic assessments. Acknowledging this uncertainty during the 
physician-patient discussion may allow for more attention to be directed towards 
the preferences and priorities of the patient. Even so, it is important to note that the 
majority of patients in this study were severely frail (i.e. CFS ≥7) as they 
approached end-of-life. Perhaps then, it is hospitalized patients who are severely 
frail or who have severe chronic disease that should be considered appropriate 
candidates for deprescribing interventions?  
This study has some limitations. Firstly, the experience described does not 
apply to the 18-29% of older people who are not hospitalized in the last year of 
life.104, 107 However, the burden of symptoms, disease and medication are 
presumably less marked in this cohort. Secondly, we may have underestimated 
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medication exposure and acute hospital care utilization because information about 
hospitalizations outside of our institution was not captured.  
In summary, hospitalizations are common and drug burden is high among 
people in the last year of life who are frequently discharged home with 
prescriptions for potentially futile medications. The STOPPFrail criteria are highly 





























Deprescribing in multi-morbid older people with polypharmacy: Agreement 
between STOPPFrail explicit criteria and Gold Standard deprescribing using 100 



















The complexity associated with multimorbidity and polypharmacy necessitates a 
systematic approach to deprescribing potentially inappropriate medications. In 
Chapter 3, I showed that STOPPFrail-defined potentially inappropriate medications 
(PIMS) are commonly prescribed for older people approaching end-of-life. While 
this was important to demonstrate, it remains unclear whether the STOPPFrail 
criteria (which comprise just 26 explicit deprescribing indicators and one implicit 
indicator) are sufficiently comprehensive enough to be used as a tool to assist 
clinicians with deprescribing decisions in older people approaching end-of-life.  
Scott and colleagues have recently proposed a 5-step deprescribing protocol 
(CEASE –Confirm current medications; Estimate risk of drug-related harm; Assess 
each medication for discontinuation; Sort/ prioritize medications for 
discontinuation; Eliminate medications according to agreed deprescribing plan).145  
The third step –assessing each medication for discontinuation - requires the user to 
answer a series of questions about each medication in the patient’s regimen 
(Figure 4.1).145 While comprehensive and patient-centred, the outcome of this step 
will depend on the knowledge, attitudes and experience of the user. Implicit 
approaches, such as CEASE, are usually time-consuming, thereby greatly limiting 
their integration into routine clinical practice.146 
The primary aim of the present study was to compare the utility of the 
structured predominantly explicit, STOPPFrail criteria with a gold standard 
comparator in frail older people with poor 1-year survival prognosis. Of the 
available published deprescribing tools, Scott’s deprescribing algorithm has the 
strongest evidence of efficacy and physician acceptabilty,173 and therefore, its use 
by a physician with expertise in clinical pharmacotherapy is likely to represent an 
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appropriate gold standard for deprescribing.  If STOPPFrail reproduces the results 
of this gold standard, then its brevity and easy usability may make it a more 
appropriate method of deprescribing in routine clinical practice for this particular 
older patient population. The secondary aim was to determine which potentially 
inappropriate or unnecessary medications are identified by the gold standard 
method but not by STOPPFrail. This information could inform future iterations of 
the STOPPFrail criteria. 
 












1. No benefit 
Significant toxicity OR no indication OR obvious 
contraindication OR cascade prescribing? 
 
No 
             2. Harm outweighs benefit 
Adverse effects outweigh symptomatic effect or 
potential future benefits? 
No 
            3. Symptom or disease drugs 
Symptoms stable or non-existent? 
No 
                  4. Preventive drugs 
Potential benefit unlikely to be realized because of 









4.2.1 Clinical cases 
To ensure that the comparison between the two deprescribing methods was valid, it 
was important to minimize external sources of variability.215 For this reason, 
structured clinical cases were prepared to ensure timely and equal access to 
information relevant to the deprescribing decision (See Appendix 3 for sample 
case). These clinical cases were based on anonymized patients included in the 
observational study that was described in Chapter 3. Each structured clinical case 
included a list of diagnoses, regular medications, functional and cognitive status 
and routine blood tests results prior to hospital discharge. All clinical cases were 
based on patients aged ≥65 years, prescribed ≥5 regular medications with moderate 
to severe frailty (Clinical Frailty Score ≥6 139). For each of the clinical cases, it was 
assumed that: 
 
i. The patient was medically stable 
ii. The patient had a poor 1-year survival prognosis 
iii. The list of diagnoses was complete and correct 
iv. Laxatives (unless potentially part of a prescribing cascade) and paracetamol 
were appropriate 
v. There were no difficulties with medication administration (e.g. dysphagia, 
poor inhaler technique etc.) unless explicitly stated 
vi. The patient’s nutritional status was satisfactory unless otherwise stated 





4.2.2 Application of deprescribing methods 
Four physicians, all trained in geriatric medicine, reviewed the clinical cases and 
identified medications that were potentially eligible for deprescribing. Two 
physicians (Dr. Denis Curtin and Dr. Desmond O’Donnell) rigidly applied 
STOPPFrail criteria while the other physicians (Dr. Kirstyn James and Dr. Tim 
Dukelow), who were not familiar with STOPPFrail criteria, identified drugs to be 
deprescribed using step 3 of the CEASE protocol (hereafter referred to as Scott’s 
deprescribing algorithm; Figure 4.1). The physicians were instructed to document 
the primary reason for each deprescribing decision. Drugs that were not eligible for 
deprescribing were classified as ‘important’. The physicians initially worked 
independently and then resolved any discrepancies in pairs to produce a final 
consensus list for each deprescribing method.  
 
4.2.3 Sample size calculation and statistical analysis 
A sample size of 100 was chosen to detect with 80% probability a Cohen’s kappa 
coefficient of 0.70 under the alternative hypothesis when Cohen’s kappa under the 
null hypothesis was 0.6. This sample size would also allow for more than 500 
medications to be evaluated. Cohen’s kappa coefficient was interpreted as poor if 
≤0.2, fair if 0.21–0.40, moderate if 0.51–0.6, substantial if 0.61–0.8 and almost 
perfect if 0.81–1.00.216 Statistical analysis was performed using SPSS® version 21. 
 
4.3 RESULTS 
4.3.1 Clinical cases 
The mean number of medications per clinical case was 10.2 (standard deviation 
3.3). The total number of medications to be evaluated (when paracetamol was 
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excluded) was 994. Most medications were taken orally (88.7%), while the 
remainder were administered by inhaled (5.1%), transdermal (3%), topical (2%), or 
subcutaneous/ intramuscular (1.3%) routes. 
 
4.3.2 Agreement between methods 
The physicians using the Scott’s deprescribing algorithm identified 524 
medications (52.7% of the total) as potentially eligible for deprescribing; the 
physicians using STOPPFrail criteria identified 412 medications for deprescribing 
(41.4%; see Table 4.1). Cohen’s kappa co-efficient was 0.60 (95% confidence 
interval 0.55 -0.65; p<0.001) indicating moderate agreement between the methods. 
With Scott’s deprescribing algorithm representing the gold standard, the sensitivity 
of STOPPFrail (i.e. the proportion of inappropriate medications correctly 
identified by STOPPFrail) was 70.2%. The specificity (i.e. the proportion of 
important medications that were correctly continued by the physicians using 
STOPPFrail) was 90.6%. The positive predictive value of STOPPFrail (i.e. the 
proportion of medications deemed inappropriate by the physicians using 
STOPPFrail that were actually inappropriate) was 89.3% while the negative 
predictive value (i.e. the proportion of medications deemed important by the 









Table 4.1: Contingency table of frequencies for medications deprescribed using 
Scott’s algorithm and STOPPFrail. 
 
 Scott’s algorithm Total 
Deprescribe Continue 
STOPPFrail Deprescribe 368 44 412 
Continue 156 426 582 
                         Total 524 470 994 
Sensitivity (368/524) 70.2% (95% CI, 66.3% to 74.1%) 
Specificity (426/470) 90.6% (95% CI, 88% to 93.2%)  
PPV (368/412) 89.3% (95% CI, 86.4% to 92.2%) 
NPV (426/582) 73.2% (95% CI, 69.6% to 76.8%) 
Legend: CI = Confidence interval; PPV = Positive predictive value; NPV = 
Negative predictive value. 
 
The primary reasons for the deprescribing decisions are summarized in Table 4.2. 
‘No valid indication’ was the primary reason for 50% of the deprescribing 
decisions made by the physicians using Scott’s deprescribing algorithm and in 
42.7% of the decisions made by the physicians using STOPPFrail. Lipid lowering 
agents, proton pump inhibitors, calcium and anti-resorptive drugs for osteoporosis 









Table 4.2: Primary reasons for deprescribing decisions by each method. 
Legend: NI = no indication; ST = significant toxicity; CI = contraindicated; CP = 
cascade prescribing.  
 
4.3.3 Discrepancies between methods 
The physicians using STOPPFrail did not identify 156 medications (29.7%) that 
were potentially eligible for deprescribing according to Scott’s deprescribing 
algorithm (Table 4.4). Antihypertensive agents, vitamin D supplements and 
laxatives (prescribed as part of a prescribing cascade) accounted for the majority 
(54.4%) of the potentially inappropriate medications that were not identified by the 





N              (%) STOPPFrail (N=412) N          (%) 
1. No 
benefit: 
               
NI 
               
ST        
               
CI 
               
CP                          
     
 
 
262           (50%) 
 
23             (4.4%)           
 
2               (0.4%) 
 
22         (4.2%) 
A2: No valid indication 176    (42.7%) 
B1: Lipid lowering 
medications 
26        (6.3%) 
C1: Antiplatelets for primary 
prevention 
9          (2.2%) 
D1: Neuroleptic 
antipsychotics 
9          (2.2%) 






77            (14.7%) 
E1: Proton pump inhibitors at 
full therapeutic dose 
51      (12.4%) 
E2: H2 receptor blocker at full 
therapeutic dose 
1          (0.2%) 
F1: Theophylline 3          (0.7%) 





48             (9.2%) 
G1: Calcium supplements 43      (10.4%) 
G2: Anti-resorptive/ bone 
anabolics 
16        (3.9%) 
G5: Long-term oral 
corticosteroids 
18        (4.4%) 
H2: Alpha blockers for 
prostatism when urethral 
catheter in place 




90             (17.2%) 
I1: Diabetic oral agents 11        (2.7%) 
J1: Multivitamin supplements 4          (1%) 
J2: Nutritional supplements 24        (5.8%) 
J3: Prophylactic antibiotics 6          (1.5%) 
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calcium supplements and continued vitamin D preparations in all cases while the 
physicians guided by Scott’s algorithm were more selective and generally 
continued these medications when a history of osteoporosis, fractures or recurrent 
falls was included in the patients’ medical history.  
 
Table 4.3: Discrepancies between the deprescribing methods: STOPPFrail 




or unnecessary drugs 
which were not identified 
by STOPPFrail (N=156) 








Vitamin D supplements 
 
 
Laxatives (as part of 
prescribing cascade) 
 
Harm outweighs benefit 
 
Antiplatelets in patients 
with advanced frailty/ 
remote history of vascular 
events 
 
Cholinesterase inhibitors in 




















































4.4  DISCUSSION 
 
In this study, application of STOPPFrail -a novel, concise explicit deprescribing 
tool designed for all physicians who commonly provide care for older adults 
approaching end of life -demonstrated moderate agreement with gold-standard 
specialist geriatrician-led deprescribing. A major barrier to deprescribing is the 
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difficulty associated with balancing risk and benefit of a specific medication for a 
particular patient. STOPPFrail addresses this difficulty by explicitly highlighting 
circumstances where commonly used medications can be reasonably discontinued. 
There is good evidence that people are much more likely to follow through on tasks 
that they see value in when those tasks are made easier for them.217 -219 It is 
therefore likely that providing explicit criteria will make the task of deprescribing  
more feasible for non-specialist physicians who care for older, adults approaching 
end of life.  
The physicians using the STOPPFrail criteria identified 70.2% of 
medications that were potentially eligible for deprescribing according to gold 
standard assessment. When medications for deprescribing were identified by the 
physicians using STOPPFrail, these medications were actually inappropriate in 
89.3% of cases. While the use of STOPPFrail does not ‘catch all’ potentially 
inappropriate medications, it is very reassuring that the great majority of the 
deprescribing decisions aligned with gold standard care. 
For both methods, the most common reason for deprescribing was ‘no valid 
indication’. This emphasizes the importance, during a medication review, of 
ensuring that each drug is linked to a diagnosis or active symptom. While 
STOPPFrail explicit criteria largely address step 2 (harm outweighs benefit) and 
step 4 (preventive drugs –benefit unlikely to be realized) of Scott’s deprescribing 
algorithm, future iterations may need to go further to address aspects of step 3 
(symptom or disease control drugs). For example, STOPPFrail does not prompt the 
physician to review symptoms such as pain which may be over-treated with 
potentially problematic medications. Furthermore, symptoms such as poor appetite, 
nausea, altered bowel habit, sedation and gait disturbance, which may represent the 
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adverse effects of drugs, are not targeted. Finally, antihypertensive therapies and 
vitamin D supplements were the most common potentially inappropriate or 
unnecessary medications that were not identified by the physicians using 
STOPPFrail. These drugs are commonly prescribed yet evidence of clear benefit, 
as well as specific guidance for use in people with advanced frailty, is lacking.220 -
223 In the absence of high quality clinical trial evidence, explicit criteria based on 
expert consensus opinion may enable physicians to make clinically sound decisions 
about the use of these medications in this particular expanding patient population.   
All structured clinical cases in this study were derived from data collected 
from a cohort of hospitalized patients who died within 1 year of their hospital 
admission. A CFS score ≥6 was used to select frail patients from this cohort which 
would ensure that the deprescribing task was credible and that a short-term risk of 
death was not unforeseeable. It is important to emphasize that, in everyday clinical 
practice, it is not recommended that a CFS score ≥6 be used to select patients for 
STOPPFrail –guided deprescribing. STOPPFrail is intended for older people 
approaching end of life for whom the goal of care is to enhance quality of life and 
minimize the risk of drug-related morbidity. As discussed in previous chapters, the 
identification of older people who are approaching end of life is likely to depend 
largely on physician experience and judgement. 
This study has some potential limitations. Firstly, it was a theoretical 
exercise using structured clinical cases. While derived from real patient data, the 
structured clinical cases do not reflect all of the complexities and nuances of real 
clinical care. However, we contend that standardization was necessary because 
external sources of variability (e.g. inequality of information) could have 
invalidated the primary aim of the study which was to compare the two methods of 
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deprescribing.215 Secondly, two physicians trained in geriatric medicine, arriving at 
deprescribing decisions through consensus, using Scott’s deprescribing algorithm, 
represented ‘gold standard’ deprescribing in this study. It is important to emphasize 
that ‘gold standard’ does not necessarily mean ‘perfect’ but rather ‘best 
available’.224 We believe the method used in this study is likely to be very close to 
the ‘best available’ deprescribing for this population of patients in most hospitals. 
In summary, the results of this study indicate that the STOPPFrail criteria 
can assist physicians in making appropriate deprescribing decisions and that, 
reassuringly, these decisions align closely with gold standard deprescribing. Before 
STOPPFrail can be recommended for use in everyday clinical practice, a 
randomized controlled trial evaluating the feasibility of applying STOPPFrail, and 
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The majority of older people transferring to a nursing home for long-term care are 
frail and have high levels of dependency. In the United States, the median length of 
stay in a nursing home before death is 5 months, while in the United Kingdom, the 
median length of stay is 15 months.169, 169 Despite limited life expectancy, these 
patients are amongst the greatest consumers of prescription medications.225 Most 
patients who transfer to nursing homes come from the acute hospital setting.226 
Therefore, there is an opportunity, prior to this transition, to conduct a formal 
medication review while the patient is under medical supervision in the hospital 
environment. 
The primary aim of the present study was to examine whether STOPPFrail-
guided deprescribing could reduce the number of medications prescribed for frail 
older people undergoing transition from hospital to nursing home care. Secondary 
aims were to determine the effect of this intervention on unscheduled hospital 
admissions, falls, fractures, antipsychotic prescribing, monthly medication costs, 




This study was a parallel-group, unblinded, randomized pragmatic clinical trial 
conducted in two acute hospitals in Cork city (Cork University Hospital and Mercy 
University Hospital). Participants were randomized to receive STOPPFrail-guided 
deprescribing plus usual pharmaceutical care or usual pharmaceutical care alone at 
the time of enrolment. The local Clinical Research Ethics Committee approved the 




Eligible participants were hospitalized older adults (aged ≥ 75 years), admitted 
from the community with acute unselected medical or surgical illness, who, 
following treatment were unable to return to home to independent living and 
consequently required long-term nursing home care. Eligible participants were 
prescribed ≥ 5 long-term medications and were severely frail. In this study, severe 
frailty was defined by (i) a Clinical Frailty Scale139 score ≥ 7, and (ii) the treating 
physician indicating that he or she “would not be surprised if the patient died in the 
next 12 months”.119 Patients were excluded if they, or, in the case of cognitively 
impaired individuals, a proxy were unwilling or unable to provide informed 
consent. 
Comprehensive multidisciplinary long-term nursing home care applications 
are reviewed fortnightly at a local placement panel meeting chaired by a consultant 
geriatrician. These applications, which include details about diagnoses, 
medications, functional and cognitive status, were used to screen for potentially 
eligible participants (see Appendix 4 for copy of application form). Patients with a 
Mini-Mental State Examination (MMSE) ≥ 24 were considered competent to 
provide written informed consent.227 For patients with a diagnosis of dementia or 
those with a MMSE < 24, a nominated proxy was required to co-sign the consent 
form. 
 
5.2.2 Data collection 
A trained research physician (the author) conducted patient and/or caregiver 
interviews and medical record reviews in order to collect the following baseline 
data before randomization: (i) current and past diagnoses; (ii) long-term regular 
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medications and pro re nata (PRN) medications (PRN medications recorded if used 
≥ 3 times in the previous week); (iii) functional status (modified Barthel Index228); 
(iv) co-morbidity status (Charlson Comorbidity Index211); (v) quality of life 
(QUALIDEM229 and ICECAP-O230) . In addition, current or recent symptoms such 
as pain, sleep disturbance, and gastrointestinal symptoms were explored in an 
unstructured manner by the research physician. After baseline data collection was 
completed, the research physician used the STOPPFrail criteria to target 
medications for deprescribing. Medications targeted for deprescribing were 
recorded in the case report form. 
Quality of life (QoL) was measured using two methods. Anticipating that a 
large proportion of participants would have advanced dementia and, therefore, 
could have difficulty completing self-reported questionnaires, the QUALIDEM 
instrument was selected.229 The QUALIDEM is completed by nursing staff or 
health-care assistants and assesses QoL across multiple domains for people at all 
stages of dementia.230 In addition, participants, where possible, or a proxy, were 
requested to complete the ICECAP-O questionnaire, which is a broad measure of 
quality of life (i.e. beyond health) and was developed for use in the economic 
evaluation of health and social care interventions in older adults.229 Both the 
QUALIDEM and ICECAP-O questionnaires have previously been used to measure 
QoL in institutional care settings231, 232 and can be viewed in Appendix 5.  
 
5.2.3 Randomization 
Participants were randomized to study arms in a 1:1 ratio using block 
randomization. Block sizes of 4 and 6 were generated using the website 
randomization.com (http://www.randomization.com) by an administrator external 
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to the study. Randomization was not stratified by hospital site. The allocation 
sequence was concealed in sequentially numbered, opaque envelopes until the 
research physician had enrolled participants, completed baseline data collection, 
and identified deprescribing targets using the STOPPFrail criteria.  
 
5.2.4 Intervention 
For participants randomized to the intervention arm, a medication withdrawal plan 
was devised by the research physician. The recommended medication withdrawal 
plan was communicated directly to one of the participant’s attending physicians 
and also documented in the participant’s medical records. Medications associated 
with an increased risk of an adverse withdrawal reaction were recommended to be 
withdrawn slowly according to a standardized trial withdrawal protocol (Table 
5.1). The attending physician judged whether or not to accept the drug withdrawal 
plan and implement the recommended changes. Because of the nature of the 
intervention, the research physician, attending physicians, and participating patients 
could not be blinded to group assignment after randomization. The intervention 
was applied at a single time point during the patients’ hospital admission, but 









Table 5.1: Protocol for withdrawal and re-instatement of drugs associated with 
the potential for acute drug withdrawal events 
 
Drug Withdrawal protocol Re-instate drug if: 
Alpha blockers for 
hypertension 
Taper medication at 
intervals of 5 days 
Increase in blood 
pressure above 160 




Taper medication at 




of dementia (BPSD), 
placing the patient or 
others at risk of harm 
Proton pump inhibitors Half dose initially. Stop 
altogether in 1 month if 
no symptoms of 
dyspepsia235 
Recurrence of dyspepsia. 
H2-receptor antagonists Half dose initially. Stop 
altogether in 1 month if 
no symptoms of 
dyspepsia 
Recurrence of dyspepsia 
Gastrointestinal 
antispasmodics 
Taper medication at 
intervals of 5 days 
Recurrence of abdominal 
cramps 
Theophylline Taper medication at 
intervals of 5 days 
Recurrence of wheeze or 
dyspnea 
Long-term oral steroids Tapering regimen will be 
individualized and will 
be based on underlying 
illness, stability of 
symptoms and duration 
of steroid use. Will be 








Diabetic oral agents Taper medication at 
intervals of 2 weeks 
Polyuria, fasting 
capillary blood glucose 
>15 or HbA1C >10% at 
6 weeks after withdrawal 
Angiotensin Converting 
Enzyme (ACE) inhibitors 
/angiotensin receptor 
blockers for diabetes 
Taper medication at 
intervals of 5 days 
Increase in blood 
pressure above 160 
mmHg systolic or 90 
mmHg diastolic 
Systemic oestrogens for 
menopausal symptoms 
Taper medication at 
intervals of 2 weeks 
Recurrence of 
menopausal symptoms 
Nutritional supplements  5% total body weight 





5.2.5 Outcome measures 
The primary outcome was the mean change in the number of long-term regularly 
prescribed medicines consumed by participants at 3 months post-randomisation. 
Short-term medicines (e.g. antibiotics, topical anti-fungal agents, topical 
corticosteroids etc.) were not included. For combination products, each ingredient 
was included as one drug as long as that ingredient was available as a single 
medicine in the contemporaneous British National Formulary (74th edition).233  
Secondary outcomes were measured at 3 months and included the following: 
 
i. Unscheduled medical reviews and emergency transfers after discharge from 
the acute hospital. 
ii. Falls and non-vertebral fractures after discharge from the acute hospital. 
iii. Changes in prescriptions of neuroleptic anti-psychotic medications. 
iv. Changes in 28-day cost of participants’ prescription medications. 
v. Changes in participants’ quality of life (measured by the QUALIDEM 
instrument and the ICECAP-O questionnaire). 
vi. Mortality.  
 
Outcome data were collected by three trained research physicians (Dr. Emma 
Jennings, Dr. Ruth Daunt, Dr. Mary Randles) who were blinded to the group 
allocation of participants. Directors of nursing in the relevant nursing homes were 
contacted by telephone and requested to complete a case report form populated 
with the relevant data fields. It was requested that a nurse or care assistant, familiar 
with the participant, complete the QUALIDEM instrument while, where possible, 
the ICECAP-O was to be completed by the same person who completed the 
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questionnaire at baseline. In some instances, the research physicians contacted the 
relevant person by telephone to complete the ICECAP-O. Twenty-eight-day cost of 
participants’ prescription drugs was calculated using a 2018 Irish pharmaceutical 
wholesaler price list, produced by Clanwilliam Health®.  For each specific 
medication dose and formulation, the lowest cost option was chosen.  
 
5.2.6 Sample size calculation and statistical analysis 
The trial was powered to detect a difference of 2.0 in the mean number of 
medications between the intervention and control groups (α = 0.5, 1-β = 0.8, 
population variance = 14 [taken from the study described in Chapter 3]) at 3 
months. Allowing for an estimated attrition rate (deaths and drop-outs) of 30%, it 
was estimated that a sample size of 160 participants (80 in each group) would be 
required.  
In the analysis of the primary outcome, we included only participants who 
completed follow-up. Because medications regimens frequently change in the final 
stages of terminal illness, we excluded deceased participants due to 
difficulties in determining final valid, verifiable medication lists. Emergency 
department presentations, hospital admissions, and mortality were determined on 
all randomized participants. We used standard descriptive statistics with study 
groups compared using χ2 or Fisher’s exact tests for categorical variables, the 
independent samples t-test for normally distributed continuous variables, and the 
Wilcoxon rank-sum test for nonparametric variables. All statistical analysis was 






5.3.1 Baseline characteristics 
Between March 27th 2018 and April 3rd 2019, 130 participants were randomized to 
receive either usual pharmaceutical care or usual pharmaceutical care 
supplemented by individualized STOPPFrail-guided deprescribing advice. 
Recruitment ended before the sample size goal of 160 was reached because of a 
requirement, due to resource constraints, to complete follow-up before the planned 
trial closure date of June 30th. Ten patients died prior to discharge from hospital, 20 
patients died prior to follow-up at 3 months, while one patient withdrew from the 
trial after enrolment (Figure 5.1). At baseline, there were no significant differences 
between the intervention (n = 65) and control (n = 65) groups in terms of age, sex 
or measures of cognitive, functional and co-morbidity status (Table 5.2). The mean 
± standard deviation (SD) number of daily medications prescribed at baseline was 
11.5 ± 3.0 in the intervention group and 10.9 ± 3.5 in the control group (p = 0.28).  
Significantly more participants in the intervention group, relative to the control 













































Screened for eligibility (n = 386) 
Excluded (n =256)  
Inclusion criteria not met: 
• <75 years (n =66) 
• < 5 drugs (n = 44) 
• SQ negative (n = 42) 
• CFS <7 (N=14) 
• Final stages of terminal illness (n=16) 
Declined participation (n = 53) 
Other reasons: 
• Insufficient time to recruit (n = 8) 
• NOK not contactable (n =8) 
• Legal issues (n = 4) 




Individuals randomized (n =130) 
Allocated to intervention 
arm (n =65) 
Received intervention care 
(n=65) 
 
Allocated to control arm  
(n =65) 
Received control care (n=65) 
 
Lost to follow-up 
Deaths prior to hospital 
discharge (n=4) 
Deaths after hospital discharge 
(n=8) 
Withdrawal from trial (n=1) 
 
Lost to follow-up 
Deaths prior to hospital 
discharge (n=6) 
Deaths after hospital 
discharge (n=12) 
Withdrawal from trial (n=0) 
 
Included in primary analysis 
(n=51) 
1 patient excluded from 
analysis (moribund, 
receiving end-of-life care) 











Table 5.2: Baseline characteristics of study participants 
Legend: CCI = Charlson Co-morbidity Index; MMSE = Mini-mental State 
Exam; PIMs = potentially inappropriate medications; PRN = pro ne 
rata; SD = standard deviation. 
 
5.3.2 STOPPFrail deprescribing recommendations 
At least one deprescribing recommendation was made for 90.8% of participants in 







Female (%) 38 (58.46%) 42 (64.61%) 0.59 
Age (SD) 85.68 (5.87) 84.49 (5.60) 0.24 
Hospital 
      Cork University Hospital 










MMSE (SD) 14.25 (7.52) 14.8 (7.37) 0.67 
Modified Barthel Index (SD) 6.83 (4.04) 7.17 (3.87) 0.63 
CCI (SD) 6.33 (1.86) 6.8 (2.31) 0.21 
Diagnoses 
      Dementia (%) 
      Heart failure (%) 
      Atrial fibrillation (%) 
      Chronic kidney disease (%) 
      Active cancer (%) 























      No. of regular medications (SD) 
      No. of PRN medications (SD) 














STOPPFrail-defined PIMs (SD) 2.41 (1.27) 2.40 (1.4) 0.948 
Medications eligible for dose reduction 
(SD) 
0.71 (0.7) 0.75 (0.73) 0.71 
Medication type 
      Anti-thrombotic 
      Antipsychotic (%) 
      Lipid lowering agents 
      Calcium 
      Analgesics 
      Anti-resorptive 
      Nutritional supplement 
      Gastric acid suppression therapy 

































for discontinuation while 0.75 ± 0.73 medications per patient were targeted for 
dose reduction. Overall, 87.8% of deprescribing recommendations were accepted 
and implemented by the attending physicians. STOPPFrail criterion A2 (i.e. Stop 
any drug without a clear clinical indication) was the most common 
recommendation triggered (44.4% of all recommendations). Lipid lowering 
therapies (criterion B1), neuroleptic antipsychotics (criterion D1), proton pump 
inhibitors (PPIs; criterion E1), anti-resorptive therapies (criterion G2), calcium 
supplements (criterion G1) and vitamin supplements (criterion J1) accounted for a 
further 40% of the deprescribing recommendations. The frequency of the 
individual STOPPFrail criteria is shown in Table 5.3. 
 
5.3.3 Primary outcome  
Data from 98 randomized participants were available for analysis for the primary 
outcome (Figure 5.1). Intervention arm patients (n = 51) and control arm patients 
(n = 47) were prescribed a mean (SD) of 11.5 (± 2.7) and 10.9 (± 3.6) regular 
prescription medications, respectively, at baseline.  The mean (SD) change in the 
number of prescribed regular medications at 3 months was -2.61 (± 2.73) in the 
intervention group and -0.36 (± 2.60) in the control group (mean difference 2.25 ± 
0.54, 95% confidence interval 1.18 -3.32, p<0.001). Of 141 medications that were 
discontinued in the intervention group, only 3 had been restarted at the 3-month 






Table 5.3: Frequency of STOPPFrail-defined potentially inappropriate 






A1: Any drug that the patient persistently fails to 
take or tolerate 
3 (1.5%) 7 (3.4%) 
A2: Any drug without clear clinical indication 75 (37.1%) 91 (44.4%) 
B1: Lipid lowering therapies 20 (9.9%) 11 (5.4%) 
B2: Alpha-blockers for hypertension 0 0 
C1: Anti-platelets for primary cardiovascular 
prevention 
7 (3.5%) 4 (2%) 
D1: Neuroleptic antipsychotics 7 (3.5%) 9 (4.4%) 
D2: Memantine 5 (2.5%) 4 (2%) 
E1: Proton Pump inhibitors 31 (15.3%) 26 (12.7) 
E2: H2 receptor antagonists 0 0 
E3: Gastrointestinal antispasmodics 1 (0.5%) 0 
F1: Theophylline 0 0 
F2: Leukotriene antagonists  1 (0.5%) 2 (1%) 
G1: Calcium supplements 23 (11.4%) 14 (6.8%) 
G2: Anti-resorptive/ bone anabolic drugs 9 (4.5%) 6 (2.9%) 
G3: Selective oestrogen receptor modulators for 
osteoporosis 
0 0 
G4: Long-term oral nonsteroidal anti-inflammatory 
drugs 
0 0 
G5: Long-term oral steroids 2 (1%) 0 
H1: 5-alpha reductase inhibitors with long-term 
bladder catheterisation 
0 0 
H2: Alpha blockers with long-term bladder 
catheterisation 
1 (0.5%) 1 (0.5%) 
H3: Muscarinic antagonists with long-term bladder 
catheterisation 
0 0 
I1: Diabetic oral agents 2 (1%) 3 (1.5%) 
I2: Angiotensin converting enzyme-inhibitors for 
diabetes 
0 1 (0.5%) 
I3: Angiotensin receptor blockers 0 0 
I4: Systemic oestrogens for menopausal symptoms 0 0 
J1: Multivitamin combination supplements 9 (4.5%) 18 (8.7%) 
J2: Nutritional supplements (other than vitamins) 4 (2.5%) 8 (3.9%) 
J3: Prophylactic antibiotics 1 (0.5%) 0 
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5.3.4 Secondary outcomes 
There were no statistically significant differences between the intervention and 
control groups for patient-related outcomes such as unscheduled hospital 
presentations, falls, fractures or mortality (see Table 5.4). QoL deteriorated 
significantly in both the intervention and control groups from baseline to three-
month follow up but there were no statistically significant differences in the mean 
change in QUALIDEM or ICECAP-O scores between groups from baseline to 
follow-up (see Table 5.5). 
Antipsychotic drugs were reduced or discontinued more often in 
intervention patients relative to control patients but, again, the differences did not 
reach statistical significance (see Table 5.6). At baseline, there were no statistically 
significant differences in the extrapolated mean (SD) monthly medication costs 
between the intervention and control groups (€240.53 ±105.57 and €225.68   
±126.68, respectively, p =0.53). However, at 3 months follow-up, the mean change 
in monthly medication cost was significantly greater in the intervention group i.e. –
€67.51 ±133.56 compared to the control group i.e. –€11.90 ±99.42 (mean 











Table 5.4: Effect of STOPPFrail-guided deprescribing on secondary outcomes 
 
Legend: *measured in final analytical sample (intervention [n=52]; control 
[n=47]); CI = confidence interval; ED = emergency department; GP 




































3 (5) 0.08 (0.03, 
0.17) 









9 (10) 0.08 (0.03, 
0.17) 




Deaths 0.18 (0.11, 
0.3) 












31 (68) 0.57 (0.43, 
0.70) 




Falls* 0.27 (0.17, 
0.40) 
14 (24) 0.30 (0.19, 
0.44) 









1 (1) 0.09 (0.03, 
0.20) 






Table 5.5: Self-reported and proxy-measured quality of life outcomes at 
baseline and 3-month follow-up 
 













        
N 63 64 - - 21 29 - - 








































        
N 61 64 - - 37 38 - - 







































Legend: N = number completed; CI = confidence interval; SD = standard deviation 
 
 










Participants who had 
successful 
discontinuation of an 
antipsychotic drug, n (%) 




Participants who had 
successful dose 
reduction of an 
antipsychotic drug, n (%) 




Legend: CI = confidence interval 
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5.4  DISCUSSION 
 
In this study of very frail older hospitalized patients with limited life expectancy, 
application of STOPPFrail criteria at a single time point resulted in a sustained and 
significant reduction in the level of polypharmacy and average aggregate monthly 
medication costs compared with usual pharmaceutical care. We found that almost 
one-in-four medications were discontinued in frail older people with polypharmacy 
using this method resulting in a 28% average reduction in monthly medication 
costs. There were no significant differences between the intervention and control 
arms in terms of important health-related outcomes including unplanned hospital 
admissions, falls, fractures, quality of life and mortality although it must be 
acknowledged that the trial was likely to have been underpowered to detect 
significant differences in these secondary outcomes.  
Other structured deprescribing methods have recently been evaluated in 
very frail older people using a randomized controlled trial design and have also 
reported a statistically significant reductions in potentially inappropriate 
prescriptions. Potter et al.174 used an implicit (Scott’s deprescribing algorithm) 
approach that required the user to answer a series of questions about each drug in 
the patient’s regimen, while Wouters et al.236 evaluated the Multidisciplinary 
Multistep Medication Review (3MR). Both methods are patient-centred and 
comprehensive but are limited by a requirement for resource-intensive processes. 
This may hinder their integration into widespread clinical practice. STOPPFrail 
overcomes these limitations by virtue of its conciseness and high inter-rater 
reliability between users of different disciplines and professional grades.148  
The most common reason for deprescribing in this trial was when a drug 
had no clear valid clinical indication (STOPPFrail criterion A2). We contend that 
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routinely clarifying whether a drug is actually indicated is fundamental to any 
formal medication review in older multi-morbid patients exposed to polypharmacy, 
particularly frailer patients with very limited survival prospects.  The remaining 
criteria in STOPPFrail are predominantly explicit and target specific drugs that, 
under usual circumstances, may be clinically indicated but are likely to be 
associated with negligible benefits or net harm in the context of advanced 
irreversible frailty and limited life expectancy. During the conduct of the trial, it 
became clear that some of the explicit criteria in STOPPFrail lacked clinical 
relevance and were very seldom, if at all, applied (e.g. systemic oestrogens for 
menopausal symptoms, selective oestrogen receptor modulators for osteoporosis). 
Furthermore, just like the study described in Chapter 4, it was evident that some 
medications, commonly prescribed in frail older people but lacking a firm evidence 
base (e.g. vitamin D therapy), were absent from STOPPFrail. In the next chapter, 
the development of an updated version of STOPPFrail, that addresses these 
shortcomings, will be described. 
This trial has some limitations. Firstly, participants were enrolled from just 
two acute hospitals in Ireland and this may limit the generalizability of our 
findings. STOPPFrail criteria were developed in the University affiliated with these 
hospitals and this may have influenced the readiness of some attending physicians 
to implement the deprescribing recommendations. Secondly, it is not possible to be 
certain of the effect of the intervention on important patient-related outcomes 
including mortality due to the relatively small sample size and short follow-up 
period. Thirdly, a cluster randomization design, which would diminish the 
possibility of contamination bias, was not used. Physicians may have 
simultaneously had both intervention and control patients under their care during 
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the trial and, through a ‘training effect’, may have applied STOPPFrail criteria 
during medication reviews of control patients. However, any possible 
contamination of this kind would increase the chance of actual effects of the 
intervention not being detected (i.e. type II error). In spite of the possible presence 
of contamination, significantly different effects of the STOPPFrail intervention 
were still observed between the groups.  
When frail older people approach end-of-life, the prescription of multiple 
medications may be burdensome or even futile in their clinical management. Our 
study provides evidence that STOPPFrail, an easily applied reliable deprescribing 
tool, substantially reduces polypharmacy and monthly medication costs in this 
patient cohort. The results, when combined with earlier studies, suggest that careful 
deprescribing can be accomplished in frail, older adults without compromising 
















































Several important properties of STOPPFrail deprescribing criteria have now been 
demonstrated: 
• The use of STOPPFrail criteria, as a method of deprescribing, has 
substantial inter-rater reliability between physicians of different disciplines 
and professional grades (kappa coefficient 0.76).148 
• As demonstrated in Chapter 4, STOPPFrail-guided deprescribing decisions 
generally align with “gold standard” geriatrician-led deprescribing (positive 
predictive value 89.3% when methods compared using 100 standardized 
clinical cases). 
• As shown in Chapter 5, implementation of STOPPFrail deprescribing 
recommendations significantly reduces medication numbers and costs for 
older people approaching end-of-life without clearly compromising well-
being.  
Despite these findings, it has become clear that STOPPFrail, as a deprescribing 
tool, has important limitations. Firstly, the method for identifying older people who 
are likely to be approaching end-of-life has limited application in a clinical setting 
(patients have to meet ALL the following criteria: end-stage irreversible pathology; 
poor 1-year survival prognosis; severe functional or cognitive impairment; 
symptom control is priority rather than prevention of disease progression).147 
Secondly, there is no reference to the role of the patient or family in the 
deprescribing decision-making process. Shared decision making is central to 
patient-centred care and clearly should be emphasized in any intervention 
involving vulnerable patients.149 Thirdly, as discussed in earlier chapters, it is clear 
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that there are several commonly prescribed medications, lacking firm evidence-
based clinical utility for frail older people, that are absent from STOPPFrail version 
1. Finally, as for all explicit criteria sets, an essential requirement is that they are 
regularly updated in line with emerging evidence and clinical guidelines. 
Therefore, the aim of this study was to prepare and validate a new version 




A review of the prognostic model and frailty literature was undertaken to devise a 
method for identifying older people approaching end-of-life. Key requirements 
were that any method would be easy-to-use and acceptable to practicing 
physicians. New deprescribing criteria were compiled by the author and his 
supervisors on the basis of experience garnered from using STOPPFrail in the 
randomized, observational, and method agreement analysis studies described in 
earlier chapters of this thesis. The proposed new criteria were then evaluated in 
terms of their clinical importance, accuracy and evidence base. Searches of 
PubMed, Google Scholar and Cochrane Library databases were undertaken. 
Searches included the drug in question along with key words including “frailty”, 
“limited life expectancy”, “end of life”, and “deprescribing”. The draft criteria, as 
well as the method for identifying older people approaching end-of-life, were then 
distributed to a panel of experts for consensus using the Delphi validation method, 
an established method of achieving consensus.237 
The panel comprised eight members with expertise in geriatric medicine, 
clinical pharmacology, psychiatry of older age, general practice and palliative 
medicine (Table 6.1). All panel members were involved in the validation of the 
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original STOPPFrail criteria.147 Accompanying the draft criteria was a supporting 
document detailing the justification and evidence base for the new criteria 
(Appendix 6).  
SurveyMonkey® software was used to facilitate the Delphi validation. Each 
draft criterion was accompanied by an explanatory statement. Panel members were 
required to choose their level of agreement for each criterion using a 5-item Likert 
scale: 1 = strongly agree; 2 = agree; 3 = neutral; 4 = disagree; 5 = strongly disagree. 
A median value of 1 or 2 and a 25th centile value of  2 (i.e. at least 75% of panel 
members agreed or strongly agreed) were required for the criterion to be included. 
Criteria with a median value of 1 or 2 but a 25th centile value of > 2 were to be 
rephrased according to the panel member suggestions and entered into the next 
Delphi validation round. Criteria with a median value of  3 were rejected. Panel 
members were encouraged to comment on criteria and provide suggestions. All 
panel member responses were anonymised and members were discouraged from 
communicating with each other during the consensus process. Repeat Delphi 
validation rounds were to be continued until agreement to include or reject was 










Table 6.1 Expert panel members who participated in the validation of 
STOPPFrail version 2 
 
Name Discipline Place of practice 
Prof. Sean O’Keeffe Geriatric medicine University College 
Hospital, Galway 
Prof. Joe Harbison Geriatric medicine St. James Hospital, 
Dublin 
Dr. Suzanne Timmons Geriatric medicine Mercy Hospital, Cork 
Prof. Stephen Byrne Clinical pharmacy University College Cork 
Prof. David Williams Clinical pharmacology Beaumont Hospital, 
Dublin 
Dr. Tony Foley General practice University College Cork 
Prof. Brian Lawlor Psychiatry of old age St. James Hospital, 
Dublin 






In Round 1 of the Delphi process, 8 new criteria, including a method for 
identifying patients approaching end-of-life, were submitted to the expert panel for 
evaluation. In addition, 7 of the original criteria, considered obsolete or less 
relevant, were submitted to the panel for re-evaluation. In these instances, panel 
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members used the Likert scale to indicate their level of agreement for removing the 
potentially obsolete criteria from the new version of STOPPFrail.  
Seven of the 8 new criteria in Round 1 had median Likert scores with 75th 
centile values of 1 or 2 and were retained as validated criteria. The remaining 
criterion, which related to the deprescribing of anti-anginal therapies (nitrates, 
nicorandil, ranolazine – “none of these anti-anginal drugs have been proven to 
reduce cardiovascular mortality or the rate of myocardial infarction. Aim to 
carefully reduce and discontinue these drugs in patients with a history of chest pain 
in the distant past [i.e. no chest pain in the previous 6 months]”, had a median 
Likert score of 1.5 but three of the panel members were ‘neutral’ about its 
inclusion. This criterion was rephrased, based on suggestions from the panel 
members, and achieved validation for inclusion in Round 2 of the Delphi process. 
Consensus was reached on removing all 7 of the potentially obsolete criteria in 
Round 1 (see Table 6.2 for details). 
STOPPFrail version 2 is shown in Table 6.3. Included in STOPPFrail 
version 2 is a method for identifying patients who are likely approaching end-of-
life as well as new criteria outlining circumstances when antihypertensive 
medications, vitamin D, folic acid, and diabetic agents can be reasonably 









Table 6.2 STOPPFrail version 1 criteria removed from the proposed version 2 
Criterion Rationale 
Alpha-blockers for hypertension  
Stringent blood pressure control is not 
required in very frail older people. Alpha 
blockers in particular can cause marked 
vasodilatation, which can result in marked 
postural hypotension, falls and injuries 
Obsolete. New criterion relating to 
anti-hypertensive therapies included 
in STOPPFrail Version 2 
Gastrointestinal antispasmodics  
Regular daily prescription of 
gastrointestinal antispasmodics agents 
unless the patient has frequent relapse of 
colic symptoms because of high risk of 
anti-cholinergic side effects  
Rarely applied. New criterion 
relating to symptomatic therapies 
included in STOPPFrail version 2.   
Selective Estrogen Receptor Modulators 
(SERMs) for osteoporosis  
Benefits unlikely to be achieved within 1 
year, increased short-intermediate term 
risk of associated ADEs particularly 
venous thromboembolism and stroke  
Rarely applied. 
Angiotensin converting enzyme (ACE)-
Inhibitors for diabetes  
Stop where prescribed only for prevention 
and treatment of diabetic nephropathy. 
There is no clear benefit in older people 
with advanced frailty with poor survival 
prognosis  
New criterion relating to anti-
hypertensive therapies included in 
STOPPFrail Version 2 
Angiotensin Receptor Blockers (ARBs) 
for diabetes 
Stop where prescribed only for prevention 
and treatment of diabetic nephropathy. 
There is no clear benefit in older people 
with advanced frailty with poor survival 
prognosis  
New criterion relating to anti-
hypertensive therapies included in 
STOPPFrail Version 2 
Systemic oestrogens for menopausal 
symptoms 
Increases risk of stroke and venous 
thromboembolic disease. Discontinue and 
only consider recommencing if recurrence 
of symptoms  
Rarely applied. 
Prophylactic Antibiotics 
No firm evidence for prophylactic 
antibiotics to prevent recurrent cellulitis 
or urinary tract infections 
There is evidence that long-term 
antibiotic therapy has a role in the 
prevention of recurrent urinary tract 






Table 6.3: STOPPFrail Version 2 
 
STOPPFrail is a list of potentially inappropriate prescribing indicators designed to 
assist physicians with deprescribing decisions. It is intended for older people with 
limited life expectancy for whom the goal of care is to optimize quality of life and 
minimize the risk of drug-related morbidity. Goals of care should be clearly defined 
and, where possible, medication changes should be discussed and agreed with patient 
and/or family. 
Appropriate patients typically meet ALL of the following criteria: 
  
1. ADL dependency (i.e. assistance with dressing, washing, transferring, 
walking)  severe chronic disease  terminal illness. 
2. Severe irreversible frailty i.e. high risk of acute medical complications and 
clinical deterioration.  
3. Physician overseeing care of patient would not be surprised if the patient 
died in the next 12 months.  
Section A: 
General 
i. Any drug that the patient persistently fails to take or tolerate 
despite adequate education and consideration of all 
appropriate formulations. 
ii. Any drug without a clear clinical indication. 
iii. Any drug for symptoms which have now resolved (e.g. pain, 





i. Lipid lowering therapies (statins, ezetimibe, bile acid 
sequestrants, fibrates, nicotinic acid, lomitapide, and 
acipimox).  
ii. Antihypertensive therapies: Carefully reduce or discontinue 
these drugs in patients with systolic blood pressure (SBP) 
persistently <130mmHg. An appropriate SBP target in frail 
older people is 130 -160mmHg. Before stopping, consider 
whether the drug is treating additional conditions (e.g. beta-
blocker for rate control in atrial fibrillation, diuretics for 
symptomatic heart failure). 
iii. Anti-anginal therapy (specifically: nitrates, nicorandil, 
ranolazine): None of these anti-anginal drugs have been 
proven to reduce cardiovascular mortality or the rate of 
myocardial infraction. Aim to carefully reduce and 
discontinue these drugs in patients who have had no reported 
anginal symptoms in the previous 12 months AND who have 




i. Anti-platelets: No evidence of benefit for primary (as distinct 
from secondary) cardiovascular prevention. 
ii. Aspirin for stroke prevention in atrial fibrillation: Aspirin 
has little or no role for stroke prevention in frail older people 
who are not candidates for anticoagulation therapy and may 





i. Neuroleptic antipsychotics in patients with dementia: Aim 
to reduce dose and discontinue these drugs in patients taking 
them for longer than 12 weeks if there are no current clinical 
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features of behavioural and psychiatric symptoms of dementia 
(BPSD). 
ii. Memantine: Discontinue and monitor in patients with 






i. Proton Pump Inhibitors:  Reduce dose of Proton Pump 
Inhibitors when used at full therapeutic dose ≥ 8 weeks, unless 
persistent dyspeptic symptoms at lower maintenance dose. 
ii. H2 receptor antagonist: Reduce dose of H2 receptor 
antagonists when used at full therapeutic dose for ≥ 8 weeks, 





i. Theophylline and aminophylline: These drugs have a 
narrow therapeutic index, have doubtful therapeutic benefit 
and require monitoring of serum levels and interact with other 
commonly prescribed drugs putting patients at an increased 
risk of ADEs.  
ii. Leukotriene antagonists (Montelukast, Zafirlukast): These 





i. Calcium supplements: Unlikely to be of any benefit in short-
term unless proven, symptomatic hypocalcaemia.  
ii. Vitamin D (ergocalciferol and colecalciferol): Lack of clear 
evidence to support the use of vitamin D to prevent falls and 
fractures, cardiovascular events, or cancer. 
iii. Anti-resorptive/bone anabolic drugs FOR OSTEOPOROSIS 
(bisphosphonates, strontium, teriparatide, denosumab) 
iv. Long-term oral NSAIDs: Increased risk of side effects (e.g. 
peptic ulcer disease, bleeding, worsening heart failure) when 
taken regularly for ≥ 2 months. 
v. Long-term oral corticosteroids: Increased risk of major side 
effects (e.g. fragility fractures, proximal myopathy, peptic 
ulcer disease) when taken regularly for ≥ 2 months. Consider 




i. Drugs for benign prostatic hyperplasia (5-alpha reductase 
inhibitors and alpha-blockers) in catheterized male 
patients: No benefit with long term bladder catheterisation.  
ii. Drugs for overactive bladder (muscarinic antagonists and 
mirabegron): No benefit in patients with persistent, 
irreversible urinary incontinence unless clear history of 




i. Anti-diabetic drugs: De-intensify therapy. Avoid HbA1c 
targets (HbA1C <7.5% [58 mmol/mol] associated with net 







In this study, I have described the development and validation of version 2 of 
STOPPFrail. The goal of STOPPFrail version 2 is to provide clinicians with a 
practical, patient-centred and, where possible, up-to-date evidence-based approach 
to deprescribing decisions in older people approaching end-of-life. Central to this 
goal is the recognition that clinicians have duties beyond the restoration and 
maintenance of health. When the limits of medical care have been reached and 
continued decline is inevitable, it may be a relief to some older people to be taking 
fewer medications.  
Recognizing when an older person is approaching end-of-life is a key 
challenge for physicians. Prognostic models, which are generally derived from 
large population-based databases, synthesize patient- and disease-related 




i. Multi-vitamin combination supplements: Discontinue when 
prescribed for prophylaxis rather than treatment of 
hypovitaminosis. 
ii. Folic acid: Discontinue when treatment course completed. 
Usual treatment duration 1-4 months unless malabsorption, 
malnutrition or concomitant methotrexate use. 
iii. Nutritional supplements: Discontinue when prescribed for 
prophylaxis rather than treatment of malnutrition. 
Disclaimer (STOPPFrail): Whilst every effort has been made to ensure that the 
potentially inappropriate prescribing criteria listed in STOPPFrail are accurate and 
evidence-based, it is emphasized that the final decision to deprescribe any drug 
referred to in these criteria rests entirely with the prescriber. It is also to be noted that 
the evidence base underlying certain criteria in STOPPFrail may change after the 
time of publication of these criteria. Therefore, it is advisable that deprescribing 
decisions should take account of current published evidence in support of or against 
the use of drugs or drug classes described in STOPPFrail. 




information to produce prognostic estimates. These estimates indicate the mortality 
risk for an average patient with a given set of risk factors under average 
circumstances. Relevant, specific information, related to the individual patient, may 
not be included in the prognostic model and, therefore, it is questionable whether 
prognostic models should be used to influence important decisions at an individual 
patient level. Regardless, there are no published non-disease-specific prognostic 
models that, to date, are validated and recommended for use in older adults.124  
In STOPPFrail version 2, I suggest using three criteria to identify patients who are 
approaching end-of-life and are, therefore, appropriate for STOPPFrail-guided 
deprescribing. The first criterion essentially describes the profile of an older people 
who may be approaching end-of-life. The validity of this criterion is supported by 
an important longitudinal study by Lunney et al. that analyzed patterns of 
functional decline in older American decedents in the last years of life.105 While 
perhaps oversimplified, the study nevertheless indicated that most older people 
experience functional decline prior to death and that the pattern of that functional 
decline tended to follow one of three trajectories depending on the profile of the 
older person (i.e. severe functional impairment, organ failure or terminal illness; 
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The second criterion is severe, irreversible, frailty. While a single operational 
definition has yet to gain widespread acceptance among experts, it is generally 
accepted that frailty is characterized by a late life vulnerability to adverse health 
outcomes, including death.128, 131, 133 Furthermore, it is generally accepted that 
frailty is a clinically recognizable state i.e. experienced physicians know it when 
they see it.239, 240 For this reason, rather than recommend a specific frailty 
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measurement tool, we recommend that attending physicians identify severe frailty 
using clinical judgement (is this older person at high risk of acute medical 
complications and clinical deterioration?), or if preferred, a frailty measurement 
tool of their choice.  The final criterion features the ‘surprise question’ which has 
been widely adopted in frameworks for assessing end of life needs.119 -121 As 
discussed in Chapter 1, the ‘surprise question’ functions as a method of separating 
those with an intermediate-to-high probability of dying (the clinician answers that 
he/she would not be surprised if the patient died within 1 year i.e. surprise question 
positive [SQ+]) from those with a low probability of dying (the clinician would be 
surprised i.e. surprise question negative [SQ-]). Two recent systematic reviews 
evaluating use of the ‘surprise question’ showed that, while, as expected,  the 
surprise question led to the detection of many ‘false positives’, the method seemed 
to be very effective at excluding patients with longer survival times (negative 
predictive value >90% in both reviews).122, 123 Therefore, as part of this wider 
prognostic assessment, the ‘surprise question’ may serve as a safety net for patients 
who are not necessarily approaching end-of-life.  
Version 2 of STOPPFrail includes new deprescribing criteria relating to 
antihypertensive therapies and vitamin D preparations. The guidance relating to 
antihypertensive therapies is influenced by European241 and Canadian242 position 
statements as well as findings from several longitudinal studies suggesting a 
possible association between intensive blood pressure control and poorer outcomes 
in older, frailer people.243, 244 While the Hypertension in the Very Elderly Trial 
(HYVET)245 and the Systolic Blood Pressure Intervention Trial (SPRINT)246 
showed that the prescription of antihypertensive therapies to lower blood pressure 
resulted in reduced mortality and cardiovascular events in robust older people, it is 
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important to note that institutionalized patients and those with an estimated life 
expectancy of less than one year were excluded from these trials. The deprescribing 
statement relating to vitamin D therapies is informed by new evidence emphasizing 
the negligible role of vitamin D in the prevention of falls, fractures, cardiovascular 
events and cancer in older people. 247-249 
Shared decision making is highlighted as an integral part of the 
deprescribing process in Version 2 of STOPPFrail. When patients engage in shared 
decision making, they feel better informed and clearer about their values.150 
Clearly, some patients (or a surrogate) may indicate a preference to continue a 
potentially inappropriate medication. In this context, while it may be helpful to try 
to understand the reasons underlying this preference, we recommend avoiding 
decisional conflict unless the drug in question is causing significant overt harm. It 
seems, however, that the great majority of older people, according to recent studies, 
would be willing to discontinue one or more medications if their physician 
indicated it was possible.154 This suggests that physicians can be reassured about 
discussing the option of deprescribing with their patients.  
In conclusion, STOPPFrail version 2 has several important updates, 
including a method for identifying older people approaching end-of-life and several 
new criteria. The new iteration is more practical, patient-centred and 
comprehensive, and careful application of the criteria, I expect, will reduce 
































7.1 SUMMARY OF RESEARCH FINDINGS 
 
From the outset, the goal of this thesis was to address two important issues. The 
first relates to the question as to whether or not there is a reliable method for 
identifying older frailer people who are likely approaching end-of-life. When end-
of-life is near apparent despite best medical efforts, directing attention towards the 
personal goals of the patient is likely to yield greater benefits than a futile, 
uncritical pursuit of chronic disease targets. These patients may benefit from a 
personalized approach that includes the deprescribing of long-term medications 
that no longer serve a useful purpose. Deprescribing involves carefully balancing 
the risks and benefits of specific medications for a particular patient and, therefore, 
has the potential to be highly challenging. This may be a barrier to deprescribing 
and opportunities to meaningfully intervene may be lost if physicians are 
uncomfortable with this practice. The second important issue, therefore, relates to 
operationalizing deprescribing i.e. how to enable physicians to deprescribe safely 
in older people approaching end-of-life.  
In Chapter 2, the HOMR model was tested in a population of older 
hospitalized patients. The exceptionally high predictive performance of the HOMR 
model, reported in earlier validation studies in North America, was substantially 
attenuated in our patient group. The results were not very surprising: the accuracy 
of prediction models is often substantially lower in new patients compared to that 
found in patients of the development population.192 -194 Further refinement and 
validation may improve the predictive accuracy of the HOMR model in older 
hospitalized patients but, until then, it cannot be recommended for use in routine 
clinical practice. For now, at least, clinical judgement remains the physician’s best 
tool for determining the likely prognosis of his/ her patients. In Chapter 6, I 
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suggested a heuristic approach to determining whether a patient is likely to be 
approaching end-of-life. Firstly, the physician determines if the patient has the 
profile of someone who is likely to be approaching end of life (i.e. terminal 
diagnosis, severe chronic disease or severe disability). Then, the physician decides 
whether the patient is at high risk of adverse health outcomes, either through 
clinical judgement or through the application of a validated frailty measurement 
tool. Finally, the physician asks ‘would I be surprised if this patient were to die in 
the next 12 months’? This approach is by no means perfect but rather is a set of 
intuitive mental shortcuts to the ease the cognitive load of making a prognostic 
assessment.  
The last year of life for the majority of older people is a period of high 
symptom burden with frequent and prolonged hospital admissions. In Chapter 3, I 
showed that patients in their final year consumed an average of 24 different 
medications while in hospital. When discharged, patients were prescribed an 
average of 2 long-term medications that were potentially inappropriate. This study 
showed that medication burden is high in the last year of life and that there could 
be an opportunity to intervene when older people are admitted to hospital.  
In Chapter 4, STOPPFrail-guided deprescribing was compared with gold 
standard geriatrician-led deprescribing using 100 standardized clinical cases. Of the 
medications that were categorized as inappropriate by the gold standard method, 
70.2% were also identified through the use of STOPPFrail. Reassuringly, the great 
majority of STOPPFrail-guided deprescribing decisions aligned with the gold 
standard. The results were important and showed that, while STOPPFrail as an 
explicit deprescribing tool has limitations, it could serve as a reasonable alternative 
to ‘gold standard’ deprescribing when this is not available. Deprescribing at end-
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of-life, therefore, need not be the sole preserve of the medication expert but rather 
would be accessible to all physicians who regularly deliver care to older, frailer 
people. Equally important, the results showed that, with the addition of new 
deprescribing criteria, STOPPFrail could be improved significantly.  
In Chapter 5, STOPPFrail-guided deprescribing was compared with usual 
pharmaceutical care using a randomized controlled trial design. Among older frail 
hospitalized patients, application of STOPPFrail resulted in a sustained and 
significant reduction in polypharmacy and medication costs compared with usual 
pharmaceutical care. There was no significant difference between the intervention 
and control arms with regard to the secondary outcome measures i.e. mortality, 
hospital admissions, falls or fractures although the trial was likely underpowered to 
detect changes in these outcomes.  
Arising from the results of studies described in Chapter 4 and 5, it was clear 
that STOPPFrail required updating to make it more practical, relevant and 
complete. Chapter 6 describes the preparation and validation of STOPPFrail 
version 2. Like its predecessor, STOPPFrail version 2 is concise, easy-to-use and 
evidence-based but now includes a new method, described above, for identifying 
older patients who approaching end-of-life as well several new deprescribing 
criteria.  
Overall, the research presented in this thesis provides a strong evidence 
base to support STOPPFrail-guided deprescribing for older people approaching 
end-of-life. Indeed, the evidence base for STOPPFrail now compares very 
favorably to other deprescribing tools for very frail older people that were 
described in a recent systematic review by Thompson et al.250 More importantly, 
the research has enhanced clarity on issues that are important to both patients and 
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healthcare providers and has implications for how clinicians practice medicine and 
manage uncertainty relating to prescribing in an ageing society.  
 
7.2 DIRECTIONS FOR FUTURE RESEARCH  
 
Larger, multicentre, randomized trials with longer follow-up times are required to 
provide further clarification on the impact of deprescribing interventions on 
outcomes such as hospital admissions, quality of life and mortality. While 
demonstrating that STOPPFrail-guided deprescribing resulted in less polypharmacy 
and reduced costs of medications was important, practicing physicians are likely to 
need further reassurance that this does not occur at the expense of patient safety 
and quality of life. As patients approach end-of-life, these outcomes may be more 
important than longevity. In the STOPPFrail trial, I measured quality of life using 
short quantitative questionnaires which may not have been sensitive enough to 
detect more subtle but relevant changes. More creative methods, including the use 
of qualitative methods with, perhaps, greater involvement of caregivers and family, 
are likely to be required in future studies.   
Some physicians, patients, and surrogates may prefer more information 
about the relative risks and benefits of discontinuing particular medications. The 
information contained within STOPPFrail Version 2 may not be enough. For this 
reason, future iterations of STOPPFrail may be improved with the addition of 
decision aids that enable stakeholders to manage uncertainty associated with 
deprescribing of certain medications. Decision aids promote shared decision 
making and enable patients to be clearer about their priorities when confronted 
with difficult choices.150 
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Table 7.1 outlines the categories and costs of medications consumed by the 
frail older people who participated in the STOPPFrail randomized trial. 
Interestingly, ‘preventives’ and ‘nutrition/ vitamin supplements’ (the categories of 
medications predominantly targeted by STOPPFrail) accounted for just 32% of the 
total number of medications but 50% of the total costs. The majority of prescribed 
drugs at baseline were in the ‘symptom/ disease control’ category. Clearly, it would 
not be appropriate to provide explicit deprescribing guidance for symptom/ disease 
control drugs: a clinical evaluation of the patient is required. Symptom burden is 
high in the last year of life and multiple medications may be necessary to achieve 
good symptom control. A reduction in the total number of regular medications may 
be a by-product of the formal medication review but the primary goal must be to 
ensure that patients are receiving the right medications to keep them well. Future 
iterations of STOPPFrail, therefore, may also be improved by including guidance 
on the pharmacological management of common problems experienced by older 
people approaching end-of-life such as pain, nausea, anxiety, and constipation.  
 
Table 7.1: Categories and costs of medications consumed by participants 
enrolled in the randomized controlled trial described in Chapter 5 
 
Preventives  
(217 drugs; 14.9% of 
total number; 14.7% of 
total cost) 
Symptom/ disease control 
(990 drugs; 67.8% of total; 
50.7% of total cost) 
Nutrition/ vitamins** 
253 items; 17.3% of 












Gastric acid suppressants 
(5.6%) 
Haematinic agents (2.7%) 
Psychiatric/hypnotic (8.3%) 





Legend: *Diuretics and b-blockers included in ‘symptom/ disease control’ 
category; **Vitamin B12 preparations included in ‘symptom/ disease control’ 
category; ***nutritional supplements alone accounted for 32.9% of the total cost of 
medications in the STOPPFrail trial 
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At the time of trial enrolment, oral nutritional supplements accounted for 
9.2% of prescribed items but 32.9% of the total costs. This finding is surprising and 
warrants further investigation. Substantial weight loss is a core component of 
frailty131, 132 and is highly predictive of future mortality.251 Malnutrition is common 
in older hospitalized patients251 and, therefore, the prescription of oral nutritional 
supplements for this patient cohort makes sense. However, while oral nutritional 
supplements produce small but consistent weight gain for older people, there is 
little evidence that they improve functional outcomes or quality of life.252, 253 In 
fact, the literature indicates that compliance with oral nutritional supplements is 
low in long-stay wards due to poor palatability.254 Future studies, therefore, should 
examine the effect of prescribing oral nutritional supplements on outcomes such as 
mealtime satisfaction, quality of life, function and mortality in older people with 
advanced frailty.  
 
 
7.3 FINAL THOUGHTS 
 
During the writing of this thesis, I have become somewhat sceptical about mortality 
prediction models, especially if they are to be used to influence important clinical 
decisions in individual frail older people. Prediction models, even when very 
accurate, tell us how an average patient with a given set of characteristics is likely 
to behave under average conditions.  The danger is that the evaluation of a patient’s 
clinical status is reduced to an aggregate score of measured risk factors. This would 
be a mistake since prediction models tell us nothing about individual patients’ 
values.  Everything that makes a patient an individual, the important things that 
define that individual’s life, are outside the realm of prediction models. While risk 
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scores and prediction models may be useful to identify groups of patients with 
shared characteristics who may benefit from a particular care pathway, I am rather 
doubtful that they should be used to influence important decisions about individual 
care. 
Prognostic certainty, for an individual patient, is unattainable. However, 
when physicians maintain very frail older people on lengthy, problematic 
medication regimens, without consideration for prognosis and goals of care, they 
may be causing undue harm. The clinical reality is that these patients inch towards 
death with steady losses of function over time.  Once frailty is established, it is 
perverse to think that medication can reverse or arrest this natural process of 
coming closer to death. While it may not be possible to accurately predict 
remaining life expectancy for frail older patients, I think it is important to at least 
consider whether they may be approaching end-of-life. In Chapter 6, I suggested a 
3-step method for identifying patients who are approaching end-of-life. It may 
suffice to simply ask “is the older person so irreversibly fragile that a relatively 
minor stressor could spell end of life?” If the answer is ‘Yes’, then I think it is less 
important whether the patient dies imminently or lives for a few years in a very 
frail state: the same interventions –assistance for daily activities, advance care 
planning, palliation and, perhaps, deprescribing –are likely to be required.  
This thesis does not intend to promote a nihilistic view of therapeutics in 
frailer older people. Rather, the intent is to emphasize the limits of certain 
medications when an older patient is approaching end-of-life. As I have shown, 
many patients approaching end-of-life are prescribed medicines for conditions or 
risk factors that do not cause symptoms but may result in adverse health outcomes 
later on – such as hypertension, hyperlipidaemia and osteoporosis. Most people 
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treated with these medications do not benefit. The population-based approach of 
treating many to help the few need not apply to older people approaching end-of-
life. Instead, these patients need their prescribers to focus on personalized care, 
prioritizing symptom relief rather than long-term prevention.  It should be 
explained to frailer older patients and their families that the deprescribing of long-
term medications is an option in these circumstances.  
Some investigators have suggested that large scale trials are required to 
precisely examine the impact of deprescribing on mortality, quality of life and 
other patient related outcomes. While this of course is pertinent, an expectation that 
deprescribing will improve these outcomes may be over-reaching. Deprescribing 
involves the withdrawal of a medical intervention and, therefore, demonstrating 
that patents are no worse off in terms of symptoms and quality of life will justify 
the process.  
Discussions about deprescribing often, appropriately, form part of a wider 
discussion around goals of care. These discussions are likely to be sensitive. It may 
be beneficial if they are initiated by a physician who knows the patient’s case very 
well, ideally the physician who will support the patient in their final illness. This 
doctor/patient familiarity and trust may be more important than the application of 
nuanced, evidence-based geriatric pharmacotherapy. My contention is that the real 
value of a tool like STOPPFrail is that it enables the general practitioner, the 
oncologist, the geriatrician -in other words, the patient’s doctor -to make clinically-
sound deprescribing decisions.  
Physicians need to remember that they have duties beyond that of restoring 
and maintaining patients in pristine health. Disability and death do not represent a 
failure of medical care but are, rather, natural processes for which science has no 
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remedy. The fundamental obligation of physicians is to relieve the suffering of 
their patients – “to cure sometimes, to relieve often, to comfort always” as the 
aphorism goes. Deprescribing for older people approaching end-of-life is the 
withdrawal of medicines but not of care; patients, families and physicians must 
understand this concept. Care in these circumstances encompasses a demonstration 
of humane concern, palliative treatment for troublesome symptoms, helping the 
patient cope with his or her final illness and above all, understanding what is 
important to the patient. Peabody, in 1927, summarized this point as follows: “One 
of the essential qualities of the clinician is interest in humanity, for the secret of the 
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discontinuation, eliminate medications according to agreed
deprescribing plan). The third step—assessing each medica-
tion for discontinuation—requires the user to answer a series
of questions about each medication in the patient’s regimen
(Fig. 1) [8]. While comprehensive and patient-centered, the
outcomeof thisstep will depend on theknowledge, attitudes,
and experience of the user. Implicit approaches, such as
CEASE, areusually time-consuming, thereby greatly limiting
their integration into routineclinical practice[9]. Morerecent-
ly, the STOPPFrail criteria (Table 1), a list of 27 indicators to
assist physicians with deprescribing decisions in frail older
individuals with poor 1-year survival prognosis, have been
validated [11]. Of the27 indicators, 26areexplicit (i.e., clearly
defined statements highlighting the potentially inappropriate
useof particular drug/drug classes in aparticular clinical situ-
ation) and one is implicit (i.e., A2: stop any drug without a
clear clinical indication). STOPPFrail criteria, which areorga-
nized according to physiological system, are concise, have
substantial inter-rater reliability [12], and are designed to be
used by physicians of all disciplines who provide care for
frailer older people on a routine basis.
The primary aim of the present study is to compare the
utility of the structured predominantly explicit STOPPFrail
criteria with a gold standard comparator in frail older people
with poor 1-year survival prognosis. Of the available pub-
lished deprescribing guides, the CEASE protocol has the
strongest evidence of efficacy and physician acceptability
[10], and therefore, its use by a physician with expertise in
clinical pharmacotherapy is an appropriate gold standard for
deprescribing. If STOPPFrail reproduces the results of this
gold standard, then its brevity and easy usability may make
it amoreappropriate method of deprescribing in routine clin-
ical practicefor thisparticular population of older people. The
secondary aim was to determine which inappropriate or un-
necessary medicationsarenot identified by STOPPFrail. This




To ensure that thecomparison between the two deprescribing
methods was valid, it was important to minimize external
sources of variability [13]. For this reason, structured clinical
cases were prepared to ensure timely and equal access to in-
f ormati on rel evant to the deprescri bi ng deci si on
(Supplementary appendix 1). Theseclinical caseswerebased
on anonymized patients included in a recent observational
study that examined the prevalenceof potentially inappropri-
ate medications in the discharge prescriptionsof older people
hospitalized in theyear prior to their death [2]. Eachstructured
clinical case included a list of diagnoses, regular medications,
functional and cognitivestatus, and routineblood tests results
prior to hospital discharge. All clinical cases were based on
patients aged ≥ 65 years, prescribed ≥ 5 regular medications
with moderate to severe frailty (Clinical Frailty Score ≥ 6
[14]). For eachof theclinical cases, it wasassumed asfollows:
i. The patient was medically stable
ii. The patient had a poor 1-year survival prognosis
iii. The list of diagnoses was complete and correct
iv. Laxatives (unless potentially part of a prescribing cas-
cade) and paracetamol were appropriate
v. Therewereno difficultieswith medication administration
(e.g., dysphagia, poor inhaler technique) unlessexplicitly
stated
vi. The patient’s nutritional status was satisfactory unless
otherwise stated
vii. Behavioral and psychological symptoms of dementia
were present only if explicitly stated
1. No benefit
Significant toxicity OR no indica on OR obvious 
contraindica on OR cascade prescribing?
2. Harm outweighs benefit
Adverse effects outweigh symptoma c effect or 
poten al future benefits?
3. Symptom or disease drugs
Symptoms stable or non-existent?
4. Preven ve drugs
Poten al benefit unlikely to be realized because of 
limited life expectancy?


















Table 1 The STOPPFrail criteria [10]
STOPPFrail is a list ofpoten ally inappropriate prescribing 
indicatorsdesignedto assist physicians with stopping such medica ons 
inolderpa ents (≥65 years) whomeetALL of the criteria listed below:
1) End-stage irreversible pathology
2) Poor one year survival prognosis
3) Severe func onal or severe cogni ve impairment or both
4) Symptom control is the priority rather than preven on of 
disease progression
The decision to prescribe/not prescribe medica ons to the pa ent, 
should also be influenced by the following issues:
1) Drug adherence/compliance is difficult
2) Administra on of the medica on is challenging
3) Monitoring of the medica on effect is challenging
4) Drug adherence/ compliance is difficult
Sec on A: General
A1:Any drug that the pa ent persistently fails to take or tolerate despite 
adequate educa on and considera on of all appropriate formula ons.
A2:Any drug without clear clinical indica on.
Sec on B: Cardiology system
B1. Lipid lowering therapies (sta ns, eze mibe, bile acid sequestrans, 
fibrates, nico nic acidand acipimox)
These medica ons need to be prescribed for a long dura on to be of 
benefit. For short-term use, the risk of adverse drug events (ADEs) 
outweighs the poten al benefits 
B2. Alpha-blockers for hypertension
Stringent blood pressure control is not required in very frail older people. 
Alpha blockers in par cular can cause marked vasodilata on, which can 
result in marked postural hypotension, falls and injuries
Sec on C: Coagula on system
C1: An -platelets
Avoid an -platelet agents for primary (as dis nct from secondary) 
cardiovascular preven on (no evidence of benefit)
Sec on D: Central Nervous System
D1. Neurolep c an psycho cs
Aim to reduce dose and discon nue these drugs in pa ents taking them 
for longer than 12 weeks if there are no current clinical features of 
behavioural and psychiatric symptoms of demen a (BPSD) 
D2: Meman ne
Discon nue and monitor in pa ents with moderate to severe demen a, 
unless
meman ne has clearly improved BPSD (specifically in frail pa ents who 
meet the criteria above)
Sec on E: Gastrointes nal System
E1. Proton Pump Inhibitors
Proton Pump Inhibitors at full therapeu c dose ≥ 8/52, unless persistent 
dyspep c symptoms at lower maintenance dose 
E2: H2 receptor antagonist
H2 receptor antagonist at full therapeu c dose for ≥ 8/52, unless 
persistent dyspep c symptoms at lower maintenance dose 
E3. Gastrointes nal an spasmodics
Regular daily prescrip on of gastrointes nal an spasmodics agents unless 
the pa ent has frequent relapse of colic symptoms because of high risk of 
an -cholinergic side effects 
Sec on F: Respiratory System
F1. Theophylline.
This drug has a narrow therapeu c index, requires monitoring of serum 
levels and interacts with other commonly prescribed drugs pu ng 
pa ents at an increased risk of ADEs 
F2. Leukotriene antagonists (Montelukast, Zafirlukast)
These drugs have no proven role in COPD, they are indicated only in 
asthma (50)
Sec on G: Musculoskeletal System
G1: Calcium supplementa on
Unlikely to be of any benefit in the short term
G2: An -resorp ve/bone anabolic drugsFOR OSTEOPOROSIS 
(bisphosphonates, stron um, teripara de, denosumab)
G3. Selec ve Estrogen Receptor Modulators (SERMs) for osteoporosis
Benefits unlikely to be achieved within 1 year, increased short-
intermediate term risk of associated ADEs par cularly venous 
thromboembolism and stroke 
G4. Long-term oral NSAIDs
Increased risk of side effects (pep c ulcer disease, bleeding, worsening 
heart failure etc.) when taken regularly for ≥ 2 months 
G5. Long-term oral steroids
Increased risk of side effects (pep c ulcer disease etc.) when taken 
regularly for ≥ 2 months. Consider careful dose reduc on and 
discon nua on 
Sec on H: Urogenital System
H1. 5-alpha reductase inhibitors
No benefit with long term urinary bladder catheterisa on 
H2. Alpha blockers
No benefit with long term urinary bladder catheterisa on
H3. Muscarinic antagonists
No benefit with long term urinary bladder catheterisa on, unless clear 
history of painful detrusor hyperac vity 
Sec on I: Endocrine System
I1. Diabe c oral agents
Aim for monotherapy. Target of HbA1c <8%/64mmol/mol. Stringent 
glycaemic control is unnecessary 
I2. ACE-Inhibitors for diabetes
Stop where prescribed only for preven on and treatment of diabe c 
nephropathy. There is no clear benefit in older people with advanced 
frailty with poor survival prognosis 
I3. Angiotensin Receptor Blockers (ARBs)
Stop where prescribed only for preven on and treatment of diabe c 
nephropathy. There is no clear benefit in older people with advanced 
frailty with poor survival prognosis 
I4. Systemic oestrogens for menopausal symptoms 
Increases risk of stroke and VTE disease. Discon nue and only consider 
recommencing if recurrence of symptoms 
Sec on J: Miscellaneous
J1. Mul -vitamin combina on supplements
Discon nue when prescribed for prophylaxis rather than treatment
J2. Nutri onal supplements (other than vitamins)
Discon nue when prescribed for prophylaxis rather than treatment 
J3: Prophylac c An bio cs
No firm evidence for prophylac c an bio cs to prevent recurrent celluli s 
or UTIs 
Disclaimer (STOPPFrail)
Whilst every effort has been made to ensure that the poten ally inappropriate prescribing criteria listed in STOPPFrail are accurate and evidence-
based, it is emphasized that the final decision to avoid or ini ate any drug referred to in these criteria rests en rely with the prescriber. It is also to be 
noted that the evidence base underlying certain criteria in STOPPFrail may change a er the me of publica on of these criteria. Therefore, it is 













Application of deprescribing methods
Four physicians, all trained in geriatricmedicine, reviewed the
clinical casesand identified medications that werepotentially
eligible for deprescribing. Two physicians (DC and DOD)
rigidly applied STOPPFrail criteriawhile theother physicians
(KJand TD), who werenot familiar with STOPPFrail criteria,
identified drugsto bedeprescribed using step 3 of theCEASE
protocol (hereafter referred to as Scott’s deprescribing algo-
rithm; Fig. 1). Thephysicianswereinstructed to document the
primary reason for each deprescribing decision. Drugs that
were not el igible for deprescribing were classif ied as
Bimportant.^ The physicians initially worked independently
and then resolved any discrepanciesin pairs to produceafinal
consensus list for each deprescribing method.
Sample size calculation and statistical analysis
A sample size of 100 was chosen to detect with 80% proba-
bility aCohen’skappacoefficient of 0.70 under thealternative
hypothesis when Cohen’s kappa under the null hypothesis
was 0.6. This sample size would also allow for more than
500 medications to be evaluated. Cohen’s kappa coefficient
was interpreted aspoor if ≤ 0.2, fair if 0.21–0.40, moderate if
0.51–0.6, substantial if 0.61–0.8, and almost perfect if 0.81–




The mean number of medications per clinical case was 10.2
(standard deviation 3.3). The total number of medications to
beevaluated (whenparacetamol wasexcluded) was994. Most
medications were taken orally (88.7%), while the remainder
were administered by inhaled (5.1%), transdermal (3%), top-
ical (2%), or subcutaneous/intramuscular (1.3%) routes.
Agreement between methods
The physicians using Scott’s deprescribing algorithm identi-
fied 524 medications (52.7% of the total) as potentially eligi-
ble for deprescribing; the physicians using STOPPFrail
criteria identified 412 medications for deprescribing (41.4%;
see Supplementary appendix 2). Cohen’s kappa coefficient
was 0.60 (95% confidence interval 0.55–0.65; p< 0.001) in-
dicating moderate agreement between the methods. With
Scott’s deprescribing algorithm representing the gold stan-
dard, the sensitivity of STOPPFrail (i.e., the proportion of
inappropr iate medications correctl y identi f i ed by
STOPPFrail) was 70.2%. The specificity (i.e., the proportion
of important medicationsthat werecorrectly continued by the
physicians using STOPPFrail) was 90.6%. The positive pre-
dictive value of STOPPFrail (i.e., the proportion of medica-
tions deemed inappropriate by the physicians using
STOPPFrail that were actually inappropriate) was 89.3%
while the negative predictive value (i.e., the proportion of
medications deemed important by the physicians using
STOPPFrail that were actually important) was 73.2%.
The primary reasons for the deprescribing decisions are
summarized in Supplementary appendix 3. BNo valid
indication^ was the primary reason for 50% of the
deprescribing decisions made by the physicians using Scott’s
deprescribing algorithm and in 42.7% of the decisions made
by the physicians using STOPPFrail. Lipid-lowering agents,
proton pump inhibitors, calcium, and anti-resorptivedrugsfor
osteoporosis accounted for 33% of the medications
deprescribed using STOPPFrail.
Discrepancies between methods
The physicians using STOPPFrail did not identify 156 medi-
cations (29.7%) that were potential l y el igible for
deprescribing (Table 2). Antihypertensive agents, vitamin D
supplements, and laxatives(prescribed aspart of aprescribing
cascade) accounted for 54.4% of thepotentially inappropriate
medications that were not identified by the physicians using
STOPPFrail. The physicians using STOPPFrail deprescribed
calcium supplementsand continued vitamin D preparationsin
all cases while the physicians guided by Scott’s algorithm
were more selective and generally continued these medica-
tions when a history of osteoporosis, fractures, or recurrent
falls was included in the patients’ medical history.
Discussion
This study is important because it shows that approximately
half of all the medications prescribed to older people ap-
proaching end of life may be unnecessary or inappropriate.
Many people with advanced frailty and polypharmacy will
not have thebenefit of acomprehensivespecialist medication
review. In this study, application of STOPPFrail—a novel,
conciseexplicit deprescribing tool designed for all physicians
who commonly providecarefor older adultsapproaching end
of life—demonstrated moderateagreement with gold standard
specialist geriatrician-led deprescribing.
A major barrier to deprescribing is thedifficulty associated
with balancing risk and benefit of a specific medication for a
particular patient. STOPPFrail addresses thisdifficulty by ex-
plicitly highlighting circumstances where commonly used
medications can be safely discontinued. There is good evi-
dence that people are much more likely to follow through on
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for them [16–18]. It is therefore likely that providing explicit
criteriawill makethetask of deprescribing moreaccessible to
non-specialist physicians who care for older adults ap-
proaching end of life.
The physicians using the STOPPFrail criteria identified
70.2% of medications that were potentially eligible for
deprescribing according to gold standard assessment. When
medications for deprescribing were identified by the physi-
cians using STOPPFrail, these medications were actually in-
appropriate in 89.3% of cases. While the use of STOPPFrail
doesnot Bcatchall^ potentially inappropriatemedications, it is
very reassuring that the great majority of the deprescribing
decisions appear to align with gold standard care.
For both methods, the most common reason for
deprescribing was Bno valid indication.^ This emphasizes
the importance, during a medication review, of ensuring that
each drug is linked to a diagnosis or active symptom. While
STOPPFrail explicit criteria largely addressstep 2 (harm out-
weighsbenefit) and step 4 (preventivedrugs—benefit unlike-
ly to be realized) of Scott’s deprescribing algorithm, future
iterations may need to go further to address aspects of step 3
(symptom or disease control drugs). For example,
STOPPFrail does not prompt the physician to review symp-
tomssuch aspain which may beover-treated with potentially
problematic medications. Furthermore, symptoms such as
poor appetite, nausea, altered bowel habit, sedation, and gait
disturbance, which may represent the adverse effects of
drugs, are not targeted. Finally, antihypertensive therapies
and vitamin D supplements were the most common inappro-
priate or unnecessary medications that were not identified by
thephysiciansusing STOPPFrail. Thesedrugsarecommonly
prescribed yet evidence of clear benefit, as well as specific
guidance for use in people with advanced frailty, is lacking
[19–22]. In theabsenceof high-quality clinical trial evidence,
explicit criteria based on expert consensus opinion may en-
able physicians to make clinically sound decisions about the
use of these medications in this particular expanding patient
population.
All structuredclinical casesin thisstudy werederived from
datacollected from acohort of hospitalized patientswho died
within 1 year of their hospital admission. A CFSscore≥ 6 was
used to select frail patients from this cohort which would
ensure that the deprescribing task was credible and that a
short-term risk of death wasnot unforeseeable. It is important
to emphasize that, in everyday clinical practice, we do not
recommend using a CFS score ≥ 6 to select patients for
STOPPFrail-guided deprescribing. STOPPFrail is intended
for older people approaching end of life for whom the goal
of care is to enhance quality of life and minimize the risk of
drug-related complications. In the absence of sensitive and
reliable prediction models [23], identifying older people who
are approaching end of life will depend largely on physician
experienceand judgment [11].
Our study has some potential limitations. Firstly, it was a
theoretical exercise using structured clinical cases. While de-
rived fromreal patient data, thestructuredclinical casesdonot
reflect the complexities and nuances of real clinical care.
However, we contend that standardization was necessary be-
cause external sources of variability (e.g., inequality of infor-
mation) could have invalidated the primary aim of the study
which wasto comparethetwo methodsof deprescribing [13].
Secondly, two physicians trained in geriatric medicine, arriv-
ing at deprescribing decisions through consensus, using
Scott’s deprescribing algorithm, represented Bgold standard^
deprescribing in this study. It is important to emphasize that
Bgold standard^ doesnot necessarily mean Bperfect^ but rath-
er Bbest availablê [24]. We believe the method used in this
study is likely to be very close to the Bbest availablê
deprescribing for thispopulation of patients in most hospitals.
In summary, the results of this study indicate that the
STOPPFrail criteriacan assist physicians in making appropri-
ate deprescribing decisions and that, reassuringly, these deci-
sionsalign closely with gold standard deprescribing. In every-
day clinical practice, wherefrail older peopleapproaching end
of life are commonly encountered by attending physicians
with variable expertise, STOPPFrail-guided deprescribing
Table 2 Discrepancies between the deprescribing methods. STOPPFrail-guided deprescribing evaluated against Bgold standard^ deprescribing
Potentially inappropriate or unnecessary drugs which were not
identified by STOPPFrail (N= 156)
N % Drugs inappropriately identified for deprescribing using
STOPPFrail criteria (N = 44)
N %
Antihypertensive agents 32 20.5 Calcium supplements 11 25
Vitamin D supplements 31 19.8 Anti-resorptive/bone anabolic drugs 12 27.3
Laxatives (as part of prescribing cascade) 22 14.1 Memantine 6 13.6
Harm outweighs benefit 16 10.2 Prednisolone 3 6.8
Antiplatelets in patients with advanced frailty/remote history of
vascular events
16 10.2 Miscellaneous 12 27.3











may be a reasonable alternative to specialist medication re-
view. Future iterations of STOPPFrail should include guid-
ance on antihypertensive therapy discontinuation as well as
prompts to the physician to explore particular symptoms
which may represent adverse drug events.
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In the following clinical cases, it can be assumed that: 
1. The patient is medically stable. 
2. The patient has a poor 1-year survival prognosis. 
3. The list of diagnoses is complete and correct. 
4. Laxatives (unless potentially part of a prescribing cascade) and paracetamol 
are appropriate. 
5. There are no difficulties with medication administration (e.g. dysphagia, 
poor inhaler technique etc.) unless explicitly stated. 
6. The patient’s nutritional status is satisfactory unless otherwise stated 
7. Behavioural and psychological symptoms of dementia are not present 
unless explicitly stated. 




Analyte Symbol Unit Reference range 
Hemoglobin Hb g/dL Males:        14.0 -
17.5 




MCV fL 80-100 
Sodium Na mmol/L 135 -145 
Potassium K mmol/L 3.4 -5.0 
Urea - mmol/L 2.9 -8.2 
Creatinine - μmol/L 50 -110 
Haemoglobin A 1c 
(glycated 
haemoglobin) 




























Past Medical History: 
1. Dementia 
2. Epilepsy 
3. Type 2 diabetes mellitus 





1. Memantine 20mg od 
2. Paroxetine 20mg od 
3. Movicol 1 sachet od 
4. Levetiracetam 500mg bd 
5. Gliclazide Modified Release 
30mg od 
6. Ferrous fumarate 305mg od 
7. Paracetamol 1g tds 
8. Sitagliptin 100mg od 
9. Metformin 1g bd 
10. Aspirin 75mg od 
11. Levothyroxine 50mcg od 
12. Donepezil 10mg od 
13. Forticreme 1 od 
14. Calcium 500mg od 














Average BP:  125/64 
 
Hb:   11.7 
MCV   80 
 
Na   138 
K  4.5 
Urea  10.7 
Creatinine 87 
 











Common Summary Assessment Report  







































Quality of Life Questionnaires used in Chapter 5 


























Table 3: QUALIDEM indicative and contra-indicative items 
No. Item Response options  
1. Is cheerful 1 
Never Rarely Sometimes Frequently  
B 
0 1 2 3  
2. Makes restless movements 1, 2 
Never Rarely Sometimes Frequently  
D 
3 2 1 0  
3. Has contact with other residents 1, 2 
Never Rarely Sometimes Frequently  
F 
0 1 2 3  
4. Rejects help from nursing assistants 1 
Never Rarely Sometimes Frequently  
A 
3 2 1 0  
5. Radiates satisfaction 1, 2 
Never Rarely Sometimes Frequently  
B 
0 1 2 3  
6. Makes an anxious impression 1, 2 
Never Rarely Sometimes Frequently  
C 
3 2 1 0  
7. Is angry 1, 2 
Never Rarely Sometimes Frequently  
A 
3 2 1 0  
8. Is capable of enjoying things in daily life 1, 2 
Never Rarely Sometimes Frequently  
B 
0 1 2 3  
9. Does not want to eat 1, 2 




3 2 1 0 9 
10. Is in a good mood 1 
Never Rarely Sometimes Frequently  
B 
0 1 2 3  
11. Is sad 1 
Never Rarely Sometimes Frequently  
C 
3 2 1 0  
12. Responds positively when approached 1, 2 
Never Rarely Sometimes Frequently  
F 
0 1 2 3  
13. Indicates that he or she is bored 1 
Never Rarely Sometimes Frequently NA 
H 
3 2 1 0 9 
14. Has conflicts with nursing assistants 1, 2 
Never Rarely Sometimes Frequently  
A 
3 2 1 0  
15. Enjoys meals 1, 2 
Never Rarely Sometimes Frequently  NA 
J 
0 1 2 3 9 
16. Is rejected by other residents 1, 2 
Never Rarely Sometimes Frequently  
G 
3 2 1 0  
17. Accuses others 1 
Never Rarely Sometimes Frequently NA 
A 
3 2 1 0 9 
18. Takes care of other residents 1 
Never Rarely Sometimes Frequently  
F 
0 1 2 3  
19. Is restless 1, 2 
Never Rarely Sometimes Frequently  
D 
3 2 1 0  
20. Openly rejects contact with others 1, 2 
Never Rarely Sometimes Frequently  
G 
3 2 1 0  
21. Has a smile around the mouth 1, 2 
Never Rarely Sometimes Frequently NA 
B 
0 1 2 3 9 
22. Has tense body language 1, 2 
Never Rarely Sometimes Frequently  
D 
3 2 1 0  
23. Cries 1, 2 
Never Rarely Sometimes Frequently  
C 
3 2 1 0  
24. Appreciates help he or she receives 1 
Never Rarely Sometimes Frequently  
A 
0 1 2 3  
25. Cuts himself/herself off from environment 1, 2 
Never Rarely Sometimes Frequently  
F 
3 2 1 0  
26. Finds things to do without help from others 1 
Never Rarely Sometimes Frequently  
I 
0 1 2 3  
27. Indicates he or she would like more help 1 
Never Rarely Sometimes Frequently NA 
E 
3 2 1 0 9 
28. Indicates feeling locked up 1 
Never Rarely Sometimes Frequently NA 
H 
3 2 1 0 9 
29. Is on friendly terms with one or more residents 1 
Never Rarely Sometimes Frequently  
F 
0 1 2 3  
30. Likes to lie down (in bed) 1, 2 
Never Rarely Sometimes Frequently NA 
J 
3 2 1 0 9 
31. Accepts help 1, 2 
Never Rarely Sometimes Frequently  
A 
0 1 2 3  
32. Calls out 1, 2 
Never Rarely Sometimes Frequently NA 
G 
3 2 1 0 9 
33. Criticizes the daily routine 1 
Never Rarely Sometimes Frequently  
A 
3 2 1 0  
34. Feels at ease in the company of others 1 
Never Rarely Sometimes Frequently  
F 
0 1 2 3  
35. Indicates not being able to do anything 1 
Never Rarely Sometimes Frequently NA 
E 
3 2 1 0 9 
36. Feels at home on the ward 1 
Never Rarely Sometimes Frequently  
H 
0 1 2 3  
37. Indicates feeling worthless 1 
Never Rarely Sometimes Frequently NA 
E 
3 2 1 0 9 
38. Enjoys helping with chores on the ward 1 
Never Rarely Sometimes Frequently  
I 
0 1 2 3  
39. Wants to get off the ward 1 
Never Rarely Sometimes Frequently  
H 
3 2 1 0  
40. Mood can be influenced in positive sense 1, 2 
Never Rarely Sometimes Frequently  
B 






                                                          
1
  People with mild to severe dementia (GDS 2 - 6). 
2
  People with very severe dementia (GDS = 7). 
3
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• STOPPFrail Version 2 is a list of prescribing indicators that highlight 
medications/medication classes that are potentially inappropriate (risks 
likely outweigh benefits) or that have negligible benefit in the context of 
reduced life expectancy. 
 
• It is recognized that physicians caring for older people approaching end of 
life will not always have expertise in geriatric pharmacotherapy; 
STOPPFrail Version 2 was developed to assist physicians with 
deprescribing medications in this particular patient population.   
 
• New criteria are based on: 
o Focused literature review 
o Findings from observational studies 
o Findings from recent method agreement analysis which compared 
use of STOPPFrail with gold standard deprescribing 
• Version 2 includes a practical method for identifying older people 
approaching end-of-life. 
 
• Version 2 recognizes core ethical principle of autonomy and emphasizes 
shared decision making. 
 
• Version 2 includes new criteria relating to antihypertensive therapy, anti-




Recognizing when older people are approaching end of life 
 
Appropriate patients typically meet ALL of the following criteria: 
1. ADL dependency (i.e. assistance with dressing, washing, transferring, 
walking)   severe chronic disease  terminal illness. 
2. Severe irreversible frailty i.e. high risk of acute medical complications and 
clinical deterioration. 
3. Physician overseeing care of patient would not be surprised if the patient 
died in the next 12 months.  
 
Rationale: 
• A 2012 systematic review by Yourman et al. concluded that there was 
insufficient evidence to recommend application of any of the available 
prognostic models for older adults.1 
 
• Even if a very precise prognostic model was available, there would 
continue to be a high degree of uncertainty when that model was used at an 
individual patient level. For example, consider a patient with a high one-year 
mortality risk –say, a 60% risk of dying within 12 months –it will not be 
clear whether the patient will be 1 of the 60 out of 100 who will die or 1 of 
the 40 who will live.  
 
• Recommending a change in goals of care solely on the basis of a prognostic 
model depersonalizes the doctor-patient interaction. It may be difficult for 
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physician to justify, to the patient and his/her family, a change in goals of 
care on this basis. 
 
• We suggest 3 criteria for identifying patients who are approaching end of 
life and are, therefore, appropriate for STOPPFrail-guided deprescribing. 
Patients suitable for STOPPFrail typically meet all 3 criteria.  
 
• The second criterion - severe irreversible frailty – refers to patients who are 
very vulnerable for developing adverse outcomes such as functional decline 
and clinical deterioration. Vulnerability to adverse outcomes is central to 
the Fried, Rockwood and consensus definitions of frailty.2-4  
 
• The first criterion describes the profile of an older person who may be 
approaching end-of-life.  
o Dependency in activities of daily living –person requires assistance 
with basic ADLs (i.e. dressing, washing, walking, transferring)  
o Severe chronic disease (i.e. recurrent exacerbations/ hospitalizations 
despite optimal medical therapy) 
o Terminal illness (e.g. cancer, motor neuron disease) 
 
• The third criterion features the ‘surprise question’ which has been widely 







1. Yourman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK. Prognostic 
indices for older adults: a systematic review. JAMA 2012; 307: 182–92. 
2. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence 
for a phenotype. J Gerontol Med Sci. 2001;56A:M146–M156. 
3. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of 
deficits. J Gerontol A Biol Sci Med Sci. 2007;62:722–7. 
4. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, et al. 
Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14:392–7. 
5. Kersun L, Gyi L, Morrison WE. Training in difficult conversations: a 
national survey of paediatric haematology-oncology and paediatric critical 
care physicians. J Palliat Med 2009;12:525-30. 
6. Gómez-Batiste X, Martínez-Muñoz M, Blay C, et al. Identifying patients 
with chronic conditions in need of palliative care in the general population: 
development of the NECPAL tool and preliminary prevalence rates in 
Catalonia. BMJ Support Palliat Care 2013;3:300-8. 
7. Dyingmatters.org: a coalition of individual and organisational members 










Autonomy and Shared Decision Making 
 
(STOPPFrail) is intended for older people with limited life expectancy for whom 
the goal of care is to enhance quality of life and minimize the risk of drug-related 
morbidity. Goals of care should be clearly defined and, where possible, medication 
changes should be discussed and agreed with patient and/or family. 
 
• Patient involvement in health care decision making is a central aspect of 
patient-centered care, and a majority of older adults report wanting to be 
involved in decision making about their health care.1-3 
 
• Multiple recent studies indicate that the great majority of older patients are 
willing to have medications deprescribed. 4-7 This suggests that clinicians 
can be reassured about broaching the topic of deprescribing with their older 
patients. 
 
• Broaching the topic of deprescribing may lead to a conversation about goals 
of care. This can be a positive step: 
o The patient and family can focus on what is important to them 
o The chances of the patient being subject to treatments of limited 
value may be reduced 
 
• The deprescribing physician may not be the patient’s primary physician 
and, therefore, may not feel that he/she is the appropriate person to initiate a 
conversation about goals of care. In addition, some patients may not wish to 
225 
 
engage in a discussion about goals of care. In this context, indicating to the 
patient that some medications may no longer be necessary (i.e., that benefits 
and risks can change over time; what was good for the patient years ago 
may no longer be so) may be the best approach.  
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1. Patient and/or a surrogate indicate a preference to continue a potentially 
inappropriate medication.  
 
It is helpful to try to understand the reasons underlying the preference to 
continue an inappropriate medication. The patient or surrogate may be 
concerned about adverse withdrawal effects of stopping the medication. 
The medication may symbolize hope to the patient, and therefore the 
recommendation to deprescribe the medication may be perceived as a loss 
of hope, abandonment, and a concern that the physician is hastening death.1  
 
The physician should address the concerns of the patient/ surrogate and 
discuss the benefits and risks of continuing the medication. Ultimately, the 
patient has the right to refuse the recommendation.  Decisional conflict 
should probably be avoided unless the medication is causing overt harm to 
the patient. 
 
2. The potentially inappropriate medication is very unlikely to be causing 
harm (e.g. vitamin D). Why not continue the medication? 
 
It may be helpful to approach this question using the “four core ethical 
principles” framework. The four principles are autonomy, non-maleficence, 




Non-maleficence refers to the principle that physicians must “first, do no 
harm”. In the context of prescribing, this involves ensuring that the risks of 
a medication do not outweigh the benefits. Regarding vitamin D, unless 
there are difficulties with drug administration, this medication is very 
unlikely to cause harm.  
 
Beneficence refers to the principle that physicians should act in the best 
interests of the patient. In the context of prescribing, this involves 
determining whether a medication can fulfill its goal by providing benefit to 
the patient. Regarding vitamin D, there is a lack of firm evidence to support 
the use of vitamin D to prevent risk of falls and fractures, cardiovascular 
events, or cancer.3-6 It is very unlikely that vitamin D provides meaningful 
benefit to patients approaching end of life.  
 
The principle of justice is important to this question and refers to the fair 
and equitable distribution of burdens and benefits to participants in society. 
Healthcare is associated with limited resources. There is an opportunity cost 
when medications are used without a good indication (resources that could 
have been put to good use elsewhere, are lost). Physicians should, therefore, 
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Reduce and discontinue these drugs in patients with systolic blood pressure (SBP) 
persistently <130mmHg. An appropriate SBP target in frail older people is 130 -
160mmHg. Before stopping, consider whether drug is treating additional 
conditions (e.g. beta-blocker for rate control in atrial fibrillation, diuretic for 
symptomatic heart failure). 
 
Rationale: 
SECTION A: RCT evidence 
SECTION B: Evidence form longitudinal/ cross-sectional studies 
SECTION C: Position statements 
 
 
SECTION A: RCT evidence 
Two recent randomized controlled trials (RCT) have evaluated the benefits of 
antihypertensive therapy in older adults. Both trials excluded participants with 
dementia and advanced frailty. 
 
1. Hypertension in the Very Elderly Trial (HYVET –NEJM 20081) 
• Double blind placebo-controlled trial, evaluated benefit of treating 
older patients (≥ 80 years) with sustained SBP ≥ 160mmHg. 
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• 3845 participants randomized within Europe, Asia, Tunisia (mean 
age 83; mean entry SBP 173mmHg in both groups.) 
• Intervention patients received indapamide  perinodpril. Target SBP 
<150mmgHg. 
• Primary outcome: stroke (fatal or non-fatal). Secondary outcomes: 
all-cause mortality, deaths from cardiovascular causes. 
• At 2 years, mean SBP in active group was 143mmHg versus 
158mmHg in the control group.  
• Median follow-up 1.8 years.  
• Results:  
o Primary outcome: 51 events in the active group vs 69 events 
in control group 
o 30% reduction in rate of stroke (p=0.06; NNT for 2 years to 
prevent 1 stroke =94) 
o All-cause mortality: 196 deaths in active group vs 235 deaths 
in control group.  
o 21% reduction in all-cause mortality (P=0.02; NNT for 2 
years to prevent 1 death =40) 
o 23% reduction in deaths from cardiovascular causes 
(p=0.06) 
 
• Note: Exclusion criteria for HYVET study included dementia, 
residence in a nursing home, life expectancy 1-year, heart failure, 




2. The Systolic Blood Pressure Intervention Trial (SPRINT –JAMA 
20162) 
• Participants randomized to an intensive SBP target of <120 versus 
standard SBP target of <140mmHg. 
• 2636 participants ≥75 years in the United States (mean age 80; mean 
entry SBP 142mmHg) 
• Primary outcome: cardiovascular events (including stroke) and 
deaths from cardiovascular causes. Secondary outcomes: all-cause 
mortality. 
• Median follow-up 3.14 years. 
• At follow-up, mean SBP in intensive group was 123mmHg while 
mean SBP in standard group was 135mmHg. 
• Results: 
o Primary outcome (fatal and non-fatal cardiovascular events): 
102 events in intensive group and 148 events in standard 
group. 
o 34% reduction in rate of primary outcome (p=0.001, NNT 
for 3.14 years to prevent 1 primary outcome = 27) 
o Secondary outcome (all-cause mortality): 73 events in 
intensive group vs 107 in standard group. 
o 33% reduction in all-cause mortality (p=0.009; NNT for 3.14 
years to prevent 1 death =41) 




• Amongst participants with frailty (characterized using a 37-item 
frailty index) and slow walking speed (<0.8m/s on a timed 4m walk 
test), there was no statistically significant difference in outcomes 
between those randomized to the intensive treatment group and the 
standard treatment group. 
• Note: Participants were excluded if life expectancy <3 years, 
dementia diagnosis, residence in a nursing home, diabetes, stroke, 
EF<35%, weight loss >10% in previous 6 months.  
 
3. A meta-analysis (Journal of Hypertension, 20103) of all the randomized 
controlled trials evaluating the treatment of hypertension in patients ≥80 
(included HYVET; did not include SPRINT) reported concluded that: 
a. Treating hypertension in very old patients reduces stroke and heart 
failure with no effect on total mortality 
b. Thiazides should be considered first-line drugs with a maximum of 
2 drugs 
c. Frail elderly and institutionalized patients were generally excluded 
from these trials. 
 
SECTION B: Evidence form longitudinal/ cross-sectional studies 
Several longitudinal studies have examined the association of blood pressure levels 




1. The Predictive Values of Blood Pressure and Arterial Stiffness in 
Institutionalized Very Aged Population Study (PARTAGE –JAMA Int 
Med 20154) 
• Evaluated association between BP and mortality risk in nursing 
home residents 
• Multi-centre (France & Italy), longitudinal study involving 1130 
nursing home residents 80 years. 
• Participants excluded if MMSE <12 or very high levels of 
dependency. 
• At baseline, BP was measured (mean of 18 different recordings over 
3 days) 
• All-cause mortality recorded at 2 years.  
• Results: 
o Patients with SBP<130mmHg who were prescribed 2 
antihypertensive drugs had an 81% excess all-cause 
mortality risk (32.2% vs 19.7%) 
o Patients with SBP <130mmHg who were prescribed <2 
antihypertensives did not have an excess mortality risk. 
 
2. Effects of Low Blood Pressure in Cognitively Impaired Elderly Patients 
Treated with Antihypertensive Drugs (JAMA Int Med 20155) 
• Evaluated association between baseline blood pressure and 
subsequent cognitive decline in 172 patients with dementia (68%) or 




• Baseline BP measured with 24-hour ambulatory monitor. 
• Median follow-up 9 months. 
• Results: 
o Low mean daytime SBP (128mmHg) was associated with 
greater cognitive decline (mean decline -2.8 on MMSE versus -
0.7 for those with higher mean SBP measurements.  Note, 
findings were only significant for those with low mean daytime 
SBP who were treated with antihypertensive medications.  
 
3. Leiden 85-plus Study (JAGS 20126) 
• Evaluated association between SBP measures at age 85 and future 
decline in physical and cognitive function. 
• Included 572 community dwelling 85-year olds in Leiden (no 
selection criteria in terms of demographic or health status: 
inhabitants of Leiden were contacted on the month of their 85th 
birthday and invited to participate.) 
• Yearly follow-up to age 90. Mean follow-up 3.2 years.  
• Results: 
o At baseline, higher BP measures were associated with less 
physical and cognitive disability at age 85. 
o Higher SBP at age 85 was associated with slower rates of 
physical and cognitive decline. 
o The relationship between higher BP and slower cognitive 




o Results were similar for those prescribed anti-hypertensive 
medications and those who were not prescribed 
antihypertensive medications.  
• Note: This study had significant limitations. Participants were 
categorized into groups at baseline based on blood pressure. 
Participants in the ‘Low SBP’ group very likely had more patients 
with dementia (it could explain accelerated cognitive and functional 
decline in this group).  
 
4. Milan Geriatrics 75+ Cohort Study (Age & Ageing 20157) 
• Evaluated association between baseline blood pressure with all-
cause mortality over a period of 10 years 
• 1587 participants recruited from outpatient Geriatric clinic in Italy.  
• Median age 82 (IQR 78 -86), median MMSE 25 (20-29). 
• Results: 
o Participants with SBP<120mmHg and 120-139mmHg had a 
1.64 (95% CI 1.21 -2.23) and 1.32 (95% CI 1.1 -1.6) fold 
increased mortality risk compared with participants with 
SBP 160 -179mmHg.  
o Higher SBP and reduced mortality risk was statistically 
significant in patients with impaired ADL functioning 
(p=0.001) and in those with MMSE<24 but not in patients 
with preserved ADL functioning (p=0.085) or those with 




SECTION C: Position statements 
1. An Expert Opinion from the European Society of Hypertension–European 
Union Geriatric Medicine Society Working Group on the Management of 
Hypertension in Very Old, Frail Subjects (Hypertension. 2016;67:820-
8258): 
 
“The 2013 ESH/ESC guidelines recommend treatment to lower SBP to 
<150 mm Hg in octogenarians in good physical and mental conditions We 
believe that this might be usefully complemented by mentioning that, while 
keeping <150 mm Hg SBP as the evidence-based target, for safety reasons 
antihypertensive drugs should be reduced or even stopped if SBP is lowered 
to <130 mm Hg, thus keeping the 150 to 130 mm Hg on-treatment SBP 
values as a safety range.” 
 
2. Canadian group consensus guideline promoting higher blood pressure 
targets for frail older adults (Dalhousie Academic Detailing Service and the 
Palliative and Therapeutic Harmonization program): 
 
Cleveland Clinic Journal of Medicine 20149 
• For frail elderly patients, consider starting treatment if the systolic 
blood pressure is 160 mm Hg or higher. 
• An appropriate target in this population is a seated systolic pressure 
between 140- and 160-mm Hg, as long as there is no orthostatic drop 
to less than 140 mm Hg upon standing from a lying position and 
treatment does not adversely affect quality of life. 
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• The blood pressure target does not need to be lower if the patient 
has diabetes. If the patient is severely frail and has a short life 
expectancy, a systolic target of 160 to 190 mm Hg may be 
reasonable. 
• If the systolic pressure is below 140 mm Hg, antihypertensive 
medications can be reduced as long as they are not indicated for 
other conditions. 
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Anti-anginal therapies (specifically: nitrates, nicorandil, ranolazine) 
None of these anti-anginal drugs have been proven to reduce cardiovascular 
mortality or the rate of myocardial infraction. Aim to carefully reduce and 
discontinue these drugs in patients with a history of chest pain in the distant past 
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Aspirin for Stroke Prevention in Atrial Fibrillation 
 
Aspirin for stroke prevention in atrial fibrillation 
Aspirin has little or no role for stroke prevention in frail older patients who are not 
candidates for anticoagulation therapy and may significantly increase bleeding 
risk. 
 
1. Lip GYH. The role of aspirin for stroke prevention in atrial fibrillation.  
  Nat. Rev. Cardiol. 2011; 8:602-606. 
2. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-
controlled, randomised trial of warfarin and aspirin for prevention of 
thromboembolic complications in chronic atrial fibrillation. The 















Vitamin D (Ergocalciferol and Colecalciferol) 
 
Vitamin D (ergocalciferol and colecalciferol) 
Low vitamin D status is likely to be a consequence of ill-health, rather than its 
cause.1 There is a lack of firm evidence to support the use of vitamin D to prevent 
risk of falls and fractures2, 3, cardiovascular events,1 or cancer.3-4 
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Drugs for Overactive Bladder (Muscarinic Antagonists and Mirabegron) 
 
Drugs for overactive bladder (muscarinic antagonists and mirabegron):  
No benefit in patients with persistent, irreversible urinary incontinence unless clear 























Diabetic Therapies (Change in Words Reflecting New Guidance) 
 
Diabetic therapies:  
De-intensify therapy. Avoid HbA1c targets (HbA1C <7.5% [58 mmol/mol] 
associated with net harm in this population). Goal of care is to minimize symptoms 
related to hyperglycaemia 
 
Reference: 
Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA; Clinical 
Guidelines Committee of the American College of Physicians. Hemoglobin A1c 
Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant 
Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the 


















There is no evidence that folic acid improves cognitive performance in older 
people. Discontinue when treatment course completed. Usual treatment duration 1-
4 months unless malabsorption, malnutrition or concomitant methotrexate use. 
 
Reference: 
Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the 
prevention and treatment of healthy elderly and demented people. Cochrane 

















Potentially Obsolete Criteria 
 
1. Alpha-blockers for hypertension 
• New antihypertensive therapy guideline 
 
2. Gastrointestinal antispasmodics 
• These medications are not prescribed very commonly. New 
recommendation (A3) to review symptoms which may have 
resolved. 
 
3. Selective Estrogen Receptor Modulators (SERMs) for osteoporosis 
• These medications are seldom prescribed 
 
4. ACE-Inhibitors for diabetes 
• New antihypertensive therapy guideline 
 
5. Angiotensin Receptor Blockers (ARBs) for diabetes 
• New antihypertensive therapy guideline 
 
6. Systemic oestrogens for menopausal symptoms 
• These medications are not very commonly prescribed 
 
7. Prophylactic Antibiotics 
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• There is evidence that long-term antibiotic therapy has a role in the 
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